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ABSTRACT 
 Factor XIII (FXIII) deficiency is a rare bleeding disorder with an average frequency of one 
case in 1-3 million and has an autosomal recessive inheritance. Previous case reports and 
case series have demonstrated an increase in the risk of miscarriage and placental abruption 
among women with FXIII deficiency.  However, there are limited data on the borderline 
level of FXIII that is needed to avoid obstetric complications. 
The aim of this study is to obtain a better understanding about the clinical course and 
outcome of FXIII deficiency among women. 
A systematic review of literature has been performed for congenital FXIII deficiency 
among women and its associated reproductive outcomes using an electronic search on 
databases. A total of 116 women were identified from 34 articles. From these cases, it was 
concluded that women with congenital FXIII deficiency suffer significant bleeding 
complications. Menorrhagia and ovulation bleeding are common gynaecological problems 
and possibly more prevalent than reported. Pregnancies in women with FXIII deficiency 
have a significant risk of miscarriage, placental abruption, preterm delivery and PPH if not 
treated. 
Pregnancy and the early post delivery period can be associated with alteration in FXIII 
activity. To establish the reference range for FXIII level during pregnancy and immediate 
puerperium, a cross sectional study of 376 healthy pregnant women was conducted to 
measure FXIII activity during first (weeks 0-12, n=116), second (weeks13-28, n=132) third 
trimester (weeks 29-42, n=128) and postnatal period (day0-3; n=30). A longitudinal study 
on 26 women from the same population was also performed throughout their period of 
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gestation. FXIII activity measured during the menstrual cycle of non-pregnant women 
(n=25) was used as a control group. There was a statistically significant reduction in the 
FXIII activity in the second and third trimester compared to the first trimester of pregnancy 
(p<0.0001). Mean FXIII level during second and third trimester and postnatal period were 
significantly lower compared to control group.  
A second study was also performed involving 32 women of reproductive age to assess the 
level of FXIII during various phases of menstrual cycle, aiming to examine possible 
changes in plasma FXIII activity during the normal menstrual cycle and whether FXIII 
activity during the menstrual phase can be correlated with heavy menstrual loss based on 
pictorial blood-assessment chart (PBAC). 
FXIII level was higher during periovulatory and secretory phases of the cycle compared to 
the menstrual phase and this difference was found to be statistically significant (p=0.036). 
No significant correlation was found between FXIII level during menstrual phase and 
BPAC score ≥ 100. 
The third study evaluates FXIII activity among 68 women with recurrent miscarriage, 
compared to 62 women with no history of pregnancy loss and at least one living child. 
Even though women with history of recurrent miscarriages had lower FXIII activity 
compare to the control group, such difference did not reach a statistical significant level 
(p=0.142). However, the cohort of women with history of miscarriage had significantly 
more cases with FXIII activity <70 IU/dL compared to the control group (p=0.034). 
In conclusion, women with congenital FXIII deficiency suffer significant obstetrics and 
gynaecological complications if not treated. Pregnancy is associated with a significant 
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decrease in FXIII activity, reaching the lowest level during the third trimester of pregnancy. 
FXIII activity was also found to be lowest during menstrual and preovulatory phase of the 
cycle.  Women with history of recurrent miscarriage are more likely to have low FXIII 
(<70 IU/dL) levels.  
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1 CHAPTER ONE:  INTRODUCTION 
1.1 General Introduction 
Factor XIII (FXIII) deficiency is a rare hereditary autosomal recessive bleeding disorder 
with an average frequency of one in 1-2 million (Peyvandi et al., 2009). There is a higher 
incidence of this condition in parts of the world that have a high rate of consanguinity 
(Bolton Maggs et al., 2004). Congenital FXIII deficiency is characterised by severe, 
delayed, spontaneous bleeding with normal coagulation screening tests.  
Women are more vulnerable to manifest a bleeding disorder because they are at high risk to 
experience bleeding challenges in their lifetime as a result of the natural cyclical bleeding 
during monthly menstrual and ovulation, as well as child birth. Women with FXIII 
deficiency often fail to produce the same levels of clotting factors as normal women, 
making them vulnerable to bleeding diathesis, delayed wound healing and adverse 
pregnancy outcome, mainly miscarriage. 
Women with congenital FXIII deficiency have been known to be a risk factor for recurrent 
early pregnancy loss (Rodeghiero et al., 1987; Inbal and Kenet, 2003; Asahina et al., 2007).  
Bleeding complications in relation to pregnancy, namely antepartum and postpartum 
haemorrhage have also been observed in women with FXIII deficiency (Saito et al., 1990; 
Mikkola et al., 1997); however, their prevalence is not clear.  Postpartum haemorrhage 
have been observed in few case reports and series of women with FXIII deficiency (Saito et 
al., 1990; Burrows et al., 2000; Ivaskevicius et al., 2010b). Haemorrhagic ovarian cysts and 
menorrhagia were also observed in women with this factor deficiency. In one case series 
involving 20 women with FXIII deficiency, menorrhagia occurred in 35% of cases, while 
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20% experienced ovarian bleeding, requiring hysterectomy in one of the cases (Lak et al., 
2003).   
 Different guidelines provide different recommendations regarding the dose and interval of 
FXIII concentrate during pregnancy as well as the level above which FXIII should be 
maintained to avoid adverse pregnancy outcome (Rodeghiero et al., 1987; Boda et al., 
1989; Asahina et al., 2000, 2007; Burrows et al., 2000). In addition, reference intervals for 
FXIII activity during each trimester of normal pregnancy have not been established yet. 
There is also lack of data in literature on the role of FXIII level in women with unexplained 
recurrent miscarriage. 
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1.2 Aims and Objectives 
This thesis aims to assess obstetric and gynaecological complications for women with 
congenital FXIII deficiency. In addition, the thesis addresses the effect of menstrual cycle 
and normal pregnancy on FXIII level. Considering the link between congenital severe 
FXIII deficiency and risk of recurrent pregnancy loss, in this thesis FXIII level was 
assessed in women with unexplained recurrent miscarriage to determine whether FXIII 
level is altered in this group of women and whether borderline levels of FXIII is also 
associated with risk of miscarriage.  
The layout of the thesis is as follows; 
• Chapter two provides an overview of FXIII, its structure, and function. In 
addition, it also provides a thorough review of FXIII deficiency, its clinical 
presentation, diagnosis and management in general. 
• Chapter three provides a systematic review of the literature of case reports and 
case series of women with congenital FXIII deficiency.  The review focuses on 
obstetric complications and outcome as well as of gynaecological problems in 
women with FXIII deficiency. The review provides data on the frequency and 
severity of menstrual problems, in particular, heavy menstrual bleeding and 
ovulation bleeding. It also review literatures on the pregnancy complications, 
mainly risk of miscarriage and bleeding during pregnancy and postpartum.  
• Chapter four is a study of the FXIII changes during pregnancy and postnatal 
period. The aim is to establish the reference ranges of FXIII level during each 
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trimester of pregnancy and early postnatal period and to assess changes in FXIII 
level in normal uncomplicated pregnancy. 
• Chapter five is a study on the variation of the FXIII level during the menstrual 
cycle. The objective is to measure and compare plasma FXIII activity during 
menstrual, late follicular, periovulatory, secretory and premenstrual phases of the 
cycle and to assess any correlation between FXIII level and menstrual blood loss. 
• Chapter six assesses the role of FXIII level in women with recurrent 
miscarriages. FXIII activity level is measured in a group of women with history 
of recurrent miscarriage and compared it to the levels of a control group of 
women with no history of miscarriage and one living child. The study aimed to 
assess any possible association between borderline plasma FXIII level and the 
risk of recurrent miscarriage. 
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2 CHAPTER TWO:  BACKGROUND AND LITERATURE REVIEW 
2.1 Historical background: 
In 1944, Robbins et al described the formation of insoluble fibrin when there was a 
combination of calcium with an unknown serum factor.  This finding was further supported 
in 1948 by Laki and Lorand who concluded that the factor was a plasma protein known as 
Fibrin Stabilizing Factor (FSF) (Robbins, 1944; Laki and Lorand, 1948). FSF was later 
given into different synonyms including Laki–Lorand or L–L factor, fibrinase, 
protransglutaminase and fibrin polymerase. In 1963, the International Committee of Blood 
Clotting Factors used the nomenclature of factor XIII as a unified abbreviation for this 
coagulation factor (Muszbek et al., 2007). 
Duckert et al (Duckert et al., 1960) published the first case report of FXIII deficiency in 
1960 in a 7 year old boy from Switzerland with prolonged bleeding following a sharp cut 
on his forehead. His previous bleeding history included umbilical bleeding at birth as well 
as a large haematoma on the head and subdural haematoma 24–36 hours following minor 
trauma. He also had slow poor wound healing. His parents were consanguineous and he had 
five siblings, of whom one brother had similar bleeding symptoms. However, his parents 
and four other siblings had no bleeding tendency. His bleeding was described as being due 
to deficiency of FXIII based on his delayed bleeding episodes, abnormal clot solubility 
assay, and thromboelastography.  
The thromboelastography test revealed a decrease in the maximal amplitude and a fast 
decline in clot size and strength, while the clot solubility assay showed an increased 
breakdown of clots in 5 M urea. Fresh Frozen Plasma (FFP) was used to treat the persistent 
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forehead bleeding and the clot solubility test returned to normal (Duckert et al., 1960; 
Schroeder et al., 2007).  
2.2 Factor XIII Structure: 
Plasma FXIII is a zymogen of tetrameric structure with two potentially active/catalytic A- 
subunits (FXIII-A) and two carrier/noncatalytic B subunits (FXIII-B), with a total 
molecular weight of 320 kDa. The average concentration of plasma FXIII (A2B2) is 14-28 
mg/L-1, corresponding to 67-133 IU/dL (Katona et al., 2000).  FXIII-A subunits in plasma 
is present only in complex form, while 50% of FXIII-B subunits is available in the free, 
non-complex form. Patients with heterozygous and homozygous FXIII deficiency are 
characterised by a reduction in the total level of the B subunit, while the free B subunit 
remains constant (Yorifuji et al., 1988). A cellular form of factor XIII (cFXIII) has been 
identified in platelets and monocytes/macrophages. This form exists as a homodimer of two 
A-subunits with a total molecular weight of 166 kDa (Muszbek et al., 1996). 
FXIII-A contains both the active thrombin cleaving site and the calcium-binding site 
required for catalytic activation (McDonagh, 1994). The gene coding for the FXIII-A 
subunit (Figure 2.1) is located on chromosome 6p24–25, and consists of 15 exons separated 
by 14 introns, which all together span over 160 kb and encoding a mature protein of 731 
amino acids. The three- dimensional X-ray crystallographic structure of recombinant FXIII-
A subunit showed that the A subunit folds into distinct domains that are arranged in the 
following sequence: the N-terminus activation peptide at residues 1-37, the beta sandwich  
at residues 38-183, the catalytic core region at residues 184-515, beta barrel 1  at residues 
516-627, and beta barrel 2 at residues 628-730 (Yee, 1994, 1996). Among the nine cysteine 
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residues in the protein, cysteine 314 represents the active site, but none of them form 
disulfide bonds. The catalytic mechanism of cross-linking by transglutaminases requires the 
catalytic triad in the central core domain which is formed through hydrogen bond 
interactions between Cys314, His373 and Asp396 (Pedersen, 1994). Two non-proline cis 
peptide bonds between Arg310 and Tyr311, and Gln425 and Phe426 have also been 
proposed to be important for FXIII function (Weiss et al., 1998).  
The B subunit of FXIII (FXIII-B) is a mosaic protein composed of 10 tandem repeats, 
called glycoprotein-1 structures or Sushi domains because of their shape. The FXIII-B 
subunit gene is located on chromosome 1q31–32.1, composed of 12 exons interrupted by 
11 introns and spans approximately 28 kb and is encoding the mature protein of 641 amino 
acids (Figure 2.2) (Bottenus et al., 1990).   
The B subunit is important in the process of stabilisation and transport of the hydrophobic 
A2 subunit in the aqueous environment of human plasma, thereby prolonging FXIII-A2 in 
circulation. Another important role is initiating the cross-linking process through localizing 
FXIII to the growing fibrin polymer, while the thrombin is still active. Localisation is 
facilitated when FXIII-B portion of the Factor XIII A2B2 molecule binds specifically to the 
gamma chains of fibrinogen leading to polymerisation, cross-linking and regulation of 
FXIII activity (Siebenlist et al., 1996; Mosesson, 2003). 
The primary formation of FXIII-A is from haematopoietic cells, while the hepatocytes 
appear to be responsible for the production of FXIII-B. The origin of FXIII subunits was 
identified from studies of hepatic and bone marrow transplantation, since recipients of a 
liver transplant experiences a change in their FXIII-B phenotype to the donor’s phenotype, 
without a similar change in FXIII-A phenotype.  Likewise, FXIII-A phenotype would 
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convert to the donor’s phenotype only after bone marrow transplantation (Wölpl et al., 
1987). The intracellular FXIII found in megakaryocytes and platelets is in the form of two 
A-subunits, while B-subunits are absent, with circulating platelets containing around 50% 
of the total FXIII found in whole blood. Cellular FXIII-A have the same immunochemical 
structure of plasma FXIII-A and thus can combine with FXIII-B to form the tetramer 
complex when released into plasma (Hsieh and Nugent, 2008).  
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Figure  2.1 Factor XIII A: gene and protein structure 
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Figure  2.2 Factor XIII B: gene and protein structure 
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2.3 Factor XIII Function: 
The main functions of FXIII are in three areas: Haemostasis, wound healing, and 
maintaining pregnancy (Muszbek et al., 1996). Other physiological functions of FXIII 
include immune defence, angiogenesis, and bone metabolism. In addition, it is involved in 
some pathological processes such as cardiovascular disease, inflammatory process, type 1 
diabetes mellitus and neoplasm (Schroeder and Kohler, 2013).   
2.3.1 Haemostasis: 
The first step of FXIII activation occurs through proteolysis in which thrombin cleaves a 
scissile peptide bond between Arg37 and Gly38, and removes the N-terminal 37 amino 
acids (activation peptide), resulting in the formation of an active transglutaminase (FXIIIa) 
(Figure 2.3). In the presence of Ca2+ and fibrin, the B subunits then dissociate from the A 
subunits resulting in a conformational change, thus leaving the active site cysteine 
accessible for the substrate (McDonagh, 1994); FXIIIa then catalyses the cross-linking of 
fibrin or other target proteins which contain appropriate glutamine and lysine residues. 
FXIIIa covalently cross-links fibrin γ-dimers through incorporating reciprocal 
intermolecular ε-(γ-glutamyl) lysine bridges between the lysine at γ406 of one γ chain and a 
glutamine at γ398/399 of another fibrin molecule. In addition, α2plasmin inhibitor, a highly 
potent inactivator of plasmin, is also cross linked to the α-chain of fibrin and fibrinogen 
through FXIIIa, while still retaining its full plasmin inhibitory activity. The rapid cross 
linking of fibrin γ-chain homodimers and also linking α2 plasmin inhibitor with fibrin α-
chain heterodimers are both followed by the slower progressive cross-linking of fibrin α-
chains into high molecular weight polymers. Thus FXIIIa improves the mechanical 
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strength, rigidity and elasticity of the clot and prevent it from being dissolved through 
fibrinolysis (Muszbek et al., 1996).  
In addition to fibrin, FXIII also cross-links several other protein substrates in plasma and 
subendothelium, such as fibronectin, von Willebrand factor, vitronectin, collagen, 
coagulation factor V, thrombospondin and plasminogen activator inhibitor type 1 (PAI-1) 
(McDonagh, 1994; Hsieh and Nugent, 2008). Unlike plasma FXIII, the platelet FXIII is not 
activated through thrombin (proteolytic activation). Instead, the platelet FXIII undergoes a 
non-proteolytic activation following exposure to a target substance and rise intracellular 
calcium level (Polgar et al., 1990).  
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Figure  2.3 Plasma FXIII activation and fibrin cross-linking 
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2.3.2 Wound healing: 
The role of FXIII in wound healing has been shown by impaired wound healing in a FXIII 
deficient patient (Vanscheidt et al., 1991) and in animal experiments (Inbal et al., 2005); 
favourable outcomes of FXIII application on wound healing and cell proliferation 
(Muszbek, 1999); antiapoptotic effect of FXIII (Dardik et al., 2003); effects on cell 
migration into the wound (Brown et al., 1993); and modulation of fibrin and connective 
tissue collagen biosynthesis (Paye et al., 1989).  Animal experiments also suggest an 
important role of FXIII in improving wound healing following myocardial infarction and 
delay the development of heart failure (Nahrendorf et al., 2006). An interesting aspect of 
FXIII in the healing process was observed following myocardial infarction. It is suggested 
that FXIII assists in the healing process of ventricular wall following infarction through 
accelerating the resolution of neutrophil response, enhancing macrophage recruitment, 
increasing collagen content and promoting angiogenesis (Nahrendorf et al., 2006, 2008).  
2.3.3 Immune defence and inflammation:  
FXIII was found to interact with the complement immune system through the incorporation 
of C3 in the fibrin clot and prolongation of fibrinolysis. FXIII also contributes in preventing 
wound infection through sequestration of bacteria in the clot such as Escherichia coli and 
Staphylococcus aureus (Wang et al., 2010; Bagoly et al., 2012). This occurs through 
activated FXIII which cross-link bacterial surface proteins into fibrin fibers as observed 
from tissue biopsies in patients with necrotizing fasciitis (Loof et al., 2011).  Another link 
between FXIII activity and the immune system comes from the observation of a lack of 
monocyte phagocytic activity in cases with FXIII deficiency even after converting to 
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macrophages. The interaction of FXIII-A with platelet protein may enhance platelet binding 
to monocyte and enhance the localisation of immune response to the area of injury 
(Ichinose, 2012).  
More recently, it was shown that human neutrophil elastase within neutrophil lymphocytes 
induce a limited cleavage of plasma or cellular FXIII and results in their activation, 
followed by much slower proteolytic inactivation (Bagoly et al., 2008).  
2.3.4 Implantation and maintaining pregnancy: 
FXIII-A has been found within macrophage cells present in the connective tissues of the 
endometrial and myometrial layers of uterine tissues obtained from normal women post 
hysterectomy (Adany and Muszbek, 1989). During embryogenesis, FXIII-A can be 
detected within chorionic mesenchyme of placenta where it appears inside the mononuclear 
round cells at the 5th week of gestation, or at the beginning of vasculogenesis. These small 
cells rapidly differentiate into large stellate cells and also increase in number from less than 
10% of total cell number at the 5th week of gestation, to around 30% by the 7th week of 
gestation (Kappelmayer et al., 1994). FXIII containing cells cannot be detected in the 
circulation before the 9th week of gestation.   
FXIII plays an important role in implantation that includes a complex interface between the 
uterus and blastocyst through the action of activated FXIII on cross linking fibrin, 
fibrinogen and fibronectin which is essential in placental attachment to uterine tissue 
(Wartiovaara et al., 1978). Implantation starts on the 7th day after ovulation. A week later, 
cytotrophoblasts and syncytiotrophoblasts invade the decidual stroma, forming a 
trophoblastic mass (Vićovac and Aplin, 1996). Two weeks after implantation, 
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cytotrophoblasts undergo active proliferation, penetrate the trophoblastic mass and invade 
the decidual stroma resulting in the formation of extravillous cytotrophoblasts. From the 6th 
to 8th week of gestation, some extravillous cytotrophoblasts will develop into the 
cytotrophoblastic shell, and the rest of extravillous cytotrophoblasts infiltrate deeply into 
the decidual stroma, forming the interstitial cytotrophoblasts. The cytotrophoblastic shell 
makes the inner surface of the maternal–fetal binding interface, while the outer surface of 
the interface is formed by the Nitabuch’s fibrinoid layer, all of which are well developed by 
the 8th week of gestation (Asahina et al., 2000; Inbal and Muszbek, 2003).  Kobayashi et al 
studied tissue samples obtained from three normal pregnant women for the presence of 
FXIII-A and FXIII-B; one sample was intrauterine implantation tissue obtained from a 
woman who underwent hysterectomy due to lyomyoma at 7 weeks of gestation, the second 
sample was tubal implantation tissue terminated during the 8th week of gestation, and the 
last was a sample of placental tissue obtained from a woman with spontaneous miscarriage 
during the 14th week of gestation. This study showed the presence of plasma-derived FXIII-
A within the extracellular spaces of extravillous cytotrophoblasts, as well as the Nitabuch’s 
layer adjacent to the cytotrophoblastic shell (Kobayashi et al., 1999).  
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Figure  2.4 Role of FXIII in placental growth and development 
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2.4 FXIII deficiency 
2.4.1 Congenital Factor XIII deficiency  
2.4.1.1 Pathogenesis and classification 
Congenital FXIII deficiency was originally classified (on the basis of antigen levels) into 
two categories; type I, characterised by deficiency of both FXIII-A and B subunits; type II, 
a deficiency of FXIII-A alone; and type III, a deficiency of FXIII-B alone (Girolami et al., 
1978, 1991). However, genetic analysis concluded that type I deficiency is mainly due to a 
defect in F13B gene rather than a combined defect in F13A and F13B genes (Ichinose, 
2001). As a result, the deficiency of FXIII-B leads to a loss of its function as a carrier for 
FXIII-A, and accelerates the clearance of FXIII-A from the circulation. This explains the 
reduction in FXIII-A level observed in type I defect (Muszbek et al., 2011a). Recently, the 
International Society on Thrombosis and Haemostasis, Scientific and Standardization 
Committee (ISTH SSC) classified congenital FXIII deficiency into two main types 
according to the genotype defect; FXIII-A deficiency, where the mutation involves F13A 
gene, and FXIII-B deficiency where the mutation involves F13B gene; The latter is rare and 
accounts for less than 5% of all cases of congenital FXIII deficiency. Both defects are 
characterised by an absence of the catalytic activity of FXIII in plasma. FXIII-A deficiency 
is further subdivided into type I, characterised by a quantitative defect resulting from 
decreased synthesis of the protein, and type II deficiency with a normal or near-normal 
concentration of functionally defective FXIII-A (Kohler et al., 2011; Muszbek et al., 2011a) 
(Table 2.1). 
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Table  2.1 Classification of FXIII deficiency according to the activity value and antigen 
concentration (Kohler et al., 2011). 
Deficiency 
Plasma FXIII 
activity 
Plasma FXIII-
A2B2 antigen 
Plasma 
FXIII-A 
antigen 
Plasma 
FXIII-B 
antigen 
Platelet 
FXIII 
activity 
Platelet 
FXIII-A 
antigen 
Inherited   
    FXIII-A deficiency 
               Type I 
               Type II 
     FXIII-B deficiency  
 
 
↓↓↓ 
↓↓↓ 
↓↓ 
 
 
↓↓↓ 
↓ -N 
↓↓↓ 
 
 
↓↓↓ 
↓-N 
↓↓ 
 
 
> 30% 
> 30% 
↓↓↓ 
 
 
↓↓↓ 
↓↓↓ 
N 
 
 
↓↓↓ 
↓-N 
N 
Auto-Ab against FXIII 
     Anti FXIII-A 
          Neutralizing 
          Non-neutralizing 
     Anti FXIII-B 
 
 
↓↓↓ 
↓↓↓ 
↓↓↓ 
 
 
↓-N 
↓↓↓ 
↓↓↓ 
 
 
↓-N 
↓↓↓ 
↓↓↓ 
 
 
> 30% 
> 30% 
↓↓↓ 
 
 
N 
N 
N 
 
 
N 
N 
N 
Other acquired 
deficiencies 
↓ ↓ ↓ ↓-N N.A N.A 
↓↓↓, highly decreased activity/concentration usually below 30%; ↓↓, considerably decreased 
activity/concentration usually 5–10%; ↓, slightly decreased activity usually in the range of 20 –70%; N, 
normal; NA, non-applicable.  
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FXIII deficiency is inherited as an autosomal recessive trait with various clinical 
presentations, and those with severe disease are homozygotes or compound heterozygotes. 
It can affect people from all races and commonly there is a history of consanguinity within 
the families of affected patients. The first published genetic mutation leading to FXIII 
deficiency was reported by Webb et al. (Webb, 1989).  At the time of writing this thesis, 
more than 100 causative mutations in FXIII genes have been reported. The number of 
reported gene mutations is 88 and 16 for the FXIII-A and FXIII-B genes respectively.  
Missense mutations are the commonest type of mutations, accounting for more than half of 
all the mutations in the FXIII A and B genes. There have been 46 missense, 23 
deletions/insertions, 9 splice site, 10 nonsense mutations reported so far for the FXIII A 
gene (Biswas et al., 2011). More than 90% of the missense mutations occur at the catalytic 
core domain. A splice site mutation in intron 5 is the most frequent mutation reported in the  
FXIII-A gene in six unrelated families from UK, Netherlands, Czech Republic Macedonia, 
Serbia and Kosovo (Schroeder et al., 2006). 
All details related to FXIII gene mutations are listed in different databases such as the 
Factor XIII Registry Database website (www.f13-database.de) and the Human Gene 
Mutation Database at the Institute of Medical Genetics in Cardiff website 
(www.hgmd.cf.ac.uk), and the ISTH website (www.isth.org). The mutations affecting the 
FXIII-A gene are mainly in the form of 62 missense, or nonsense, mutations (Table 2.2), in 
addition to other forms of mutations such as splice, insertion, and deletion (International 
Society on Thrombosis & Haemostasis, 2011). The most commonly known FXIII-A 
polymorphisms are in the form of Val34Leu, Tyr204Phe, Leu564Pro, Val650Ile, and 
Glu651Gln. In a case report, the FXIII-B gene defect was due to loss of the  last five sushi 
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domains in the B-subunit following a duplication in exon 7 (c.1155_1158dupACTT) 
(Ivaskevicius et al., 2010b). Other forms of FXIII-B mutations are listed in Table  2.3. 
The common Val34Leu polymorphism is caused by defect in the FXIII gene characterised 
by a G-to-T transition (FXIII G103T) in exon 2 of the gene encoding for FXIII-A, resulting 
in a valine (V)-to-leucine (L) substitution at the 34th amino acid (Kobbervig and Williams, 
2004). This form of gene mutation is not associated with changes in FXIII plasma 
concentration, but can alter FXIII activity. In carriers of FXIII G103T mutation, activation 
of FXIII-A by thrombin was found to occur two- to threefold more rapidly affecting clot 
stability. The thrombin-induced catalytic cleavage of FXIII-A changes the structure of the 
cross-linked fibrin, resulting in the formation of a fibrin clot made up of thinner fibers and 
weaker fibrin mesh. This mechanism has been suggested to be the underlying cause for 
increased risk of spontaneous miscarriage in women with Val34Leu polymorphism. 
(Dossenbach-Glaninger et al., 2003). 
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Table  2.2 FXIII-A missense /nonsense mutations (International Society on 
Thrombosis & Haemostasis, 2011). 
 
Exon Amino acid change Domain  Reference 
2 His64Tyr b-sandwich   Ivaskevicius et al. 2007 
3 
Asn60Lys 
Arg77Cys 
Arg78Cys 
Arg77His 
Glu102Lys 
Tyr69stop 
b-sandwich 
b-sandwich 
b-sandwich 
b-sandwich 
b-sandwich 
b-sandwich 
 Anwar  R et al. 1995 
Duan et al. 2002 
Halverstadt et al. 2006 
Peyvandi et al. 2004 
Anwar 2002 
Jayandharan et al 2006                                    
4 
Met159Arg 
Arg171Stop 
Arg174Stop 
Pro186Leu 
b-sandwich 
b-sandwich 
b-sandwich 
Core 
 Schroeder et al. 2006 
Standen and Bowen 1993 
Zheng et al. 2009 
Castaman et al. 2008 
5 
Gly210Arg 
Gly215Arg 
Y204Stop  
Core 
Core 
Core 
 Vesokovsky et al. 2004 
Schroeder et al. 2006 
Souri et al, 2012 
6 
Leu235Arg 
Met242Thr 
Arg252Ile 
Arg260Cys 
Arg260Leu 
Arg260His 
Gly262Glu 
Ser263Phe 
Core 
Core 
Core 
Core 
Core 
Core 
Core 
Core 
 Birben et al. 2003 
Mikkola et al. 1994 
Mikkola et al. 1996 
Ichinose 1998 
Vysokovsky et al, 2004 
Kangsadalamai 1999 
Onland et al. 2005 
Jayandharan et al. 2006 
7 
Tyr283Cys 
Ser295Arg 
Val316Phe 
Ala318Val 
Lys257Glu 
Pro289Arg 
Core 
Core 
Core 
Core 
Core 
Core 
 Souri et al. 2001 
Anwar R et al. 2000 
Onland et al. 2005 
Vysokovsky et al, 2004 
Ivaskevicius et al. 2007 
Ivaskevicius et al. 2010 
8 
Arg326Gln 
Arg326Stop 
Leu354Pro 
Core 
Core 
Core 
 Mikkola et al. 1996 
Anwar 2005 
Anwar et al. 2001 
9 
Trp375Cys 
Ala378pro 
Arg382Ser 
Ala394Val 
Thr398Asn 
Gln400Stop 
Gly390Stop 
Core 
Core 
Core 
Core 
Core 
Core 
Core 
 Schroeder et al. 2006 
Ivaskevicius et al. 2007 
Peyvandi et al. 2003 
Izumi 1998 
Vysokovsky et al, 2004 
Kangsadalampai et al 1996 
Ivaskevicius et al. 2010 
10 
Arg408Gln 
Ser413Leu 
Ser413Trp 
Val414Phe 
Gly420Ser 
Tyr441Stop 
Core 
Core 
Core 
Core 
Core 
Core 
 Anwar R et al. 1995 
Niya et al. 1999 
Duan et al. 2003 
Aslam 1997 
Kangsadalampai et al 1996 
Anwar. 1995 
11 
Gly501Arg 
Tyr441stop 
Thr449Ile 
Core 
Core 
Core 
 Board 1993 
Anwar R et al. 1995 
Maak et al, 2010 
12 
Leu498Pro 
Gly501Arg 
Gly562Arg 
Asn541Lys 
Arg430Gln 
Core 
Core 
Barrel 1 
Barrel 1 
Barrel 1 
 Mikkola et al. 1996 
Board 1993 
Takahashi et al., 1998 
Birben et al. 2002 
Ivaskevicius et al. 2010 
13 Leu604Pro Gly592Ser, Arg611His 
Barrel 1 
Barrel 1 
 Ivaskevicius et al. 2007 
Ivaskevicius et al. 2010 
14 
Leu660Pro 
Arg661Stop 
Leu667Pro 
Trp664stop, Asp668Gly 
Barrel 2 
Barrel 2 
Barrel 2 
Barrel 2 
 Inbal et al. 1997 
Mikkola et al. 1994 
Aslam 1995 
Ivaskevicius et al. 2010 
15 
Trp691Stop 
His716Arg 
Arg703Trp 
Ser708Asn 
S708R 
Barrel 2 
Barrel 2 
Barrel 2 
Barrel 2 
Barrel 2 
 Anwar 2005 
Schroeder et al. 2006 
Wu et al. 2006 
Castaman et al, 2008 
Souri et al, 2012 
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Table  2.3 FXIII-B mutations (International Society on Thrombosis & Haemostasis, 
2011) 
Location Amino acid change Domain Reference 
Intron 1 IVS1-2 del A*  Koseki et al, 2001 
Intron 1 
Exon 8 
IVS1-2 del A* 
Cys430Phe 
 
Sushi 7 
Saito et al, 1990 
Intron 1 
Exon 9 
IVS1-2 del A* 
nt 1498 del G 
 
Sushi 8 
Koseki et al, 2001 
Exon 2 Cys5Arg Sushi 1 Ivaskevicius et al, 2010 
Intron 2 IVS2-1 G>C  Ivaskevicius et al, 2010 
Exon 3 
nt 299 ins AAC* Sushi 2 Izumi et al, 1996 
Souri et al, 1998 
Exon 3 Ile81Asn* Sushi 2 Saito et al, 1990 
Exon 3 Leu116Phe Sushi 2 Ivaskevicius et al, 2010 
Intron 3 IVS3 -1 G>C  Ivaskevicius et al, 2010 
Exon 4 nt 471 del ATT Sushi 3 Ivaskevicius et al, 2010 
Exon 5 Val217Ile Sushi 4 Ivaskevicius et al, 2010 
Exon 7 Cys316Phe* Sushi 6 Ivaskevicius et al, 2010 
Exon 7 nt 1158 ins ACTT Sushi 6 Ivaskevicius et al, 2010 
Exon 8 Val401Glu Sushi 7 Ivaskevicius et al, 2010 
Exon 8 Pro428Ser Sushi 7 Ivaskevicius et al, 2010 
Exon 12 Nt1959 ins T Sushi 12 Ivaskevicius et al, 2010 
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2.4.1.2 Prevalence and Clinical manifestations  
Congenital FXIII deficiency, where there is < 1% of the normal level of FXIII activity, is a 
rare bleeding disorder with an estimated incidence of one in 1-2 millions (Peyvandi et al., 
2009).  Most cases of congenital FXIIII deficiency are characterised by a severe bleeding 
tendency, as well as poor wound healing and spontaneous miscarriage among affected 
women (Kobayashi et al., 1990; Asahina et al., 1998, 2000, 2007; Burrows et al., 2000; 
Dardik et al., 2006).  
The earliest manifestation of this condition is in form of umbilical bleeding presenting few 
days after delivery, making it a characteristic sign and the most common symptom reported 
in about 80% of the cases (Anwar and Miloszewski, 1999; Anwar et al., 2002).  Extensive 
bleeding following minor trauma has been found to be significantly associated with 
heterozygous deficiency of FXIII. Bleeding into the skin and subcutaneous tissues can lead 
to extensive bruises (Mahmoodi et al., 2011).  Intracranial haemorrhage (ICH) occurred in 
up to 30% of reported cases. This is more frequent than in any other inherited clotting 
disorder, such as haemophilia A or B, and is considered the leading cause of mortality or 
morbidity among patients with congenital FXIII deficiency  (Duckert, 1972; Karimi, 2009).  
In addition, mouth and gum bleeding following tooth extraction can be a recurrent and 
serious problem. Bleeding into muscles and the periarticular area is also common and can 
be severe requiring hospital admission. Characteristically, intramuscular bleeding can occur 
following heavy exercise, even without any history of direct trauma (Anwar and 
Miloszewski, 1999). The frequency of bleeding in patients with congenital FXIII deficiency 
are summarised in Table 2.3. While menorrhagia is considered a common and major 
symptom in many bleeding disorders like von Willebrand disease and Factor XI deficiency, 
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its prevalence and impact among women with FXIII deficiency is still not clear (Peyvandi 
et al., 2011b). In a case series by Lak et al from Iran, a history of menorrhagia was reported 
in 7/20 (35%) women with congenital FXIII deficiency (Lak et al., 2003). In addition, a 
review of published case reports by Burrow et al in 2000 showed Menorrhagia as a clinical 
symptom in 7/11 (64%) women with FXIII deficiency (Burrows et al., 2000). 
A recent study on the European Network of Rare Bleeding Disorder proposed a grading 
system of bleeding among patients with coagulation disorder (Peyvandi et al., 2012): 
1) Asymptomatic:  No documented bleeding episode 
2) Grade I bleeding:  Post-traumatic or post drug ingestion 
3) Grade II bleeding:  Spontaneous minor bleeding (bruising, ecchymosis, oral cavity 
bleeding, epistaxis and menorrhagia) 
4) Grade III bleeding: Spontaneous major bleeding (Intramuscular haematoma, 
haemarthrosis, CNS, Gastrointestinal and umbilical cord bleeding) 
Based on the same study above, FXIII activity that was necessary for patients to remain 
asymptomatic was 31 IU/dL. For those with Grade I bleeding the mean FXIII activity was 
16.85 IU/dL, for Grade II was 2.6 IU/dL, and Grade III was 0.IU/dL (Peyvandi et al., 
2012). 
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Table  2.4 Bleeding sites in patients with congenital FXIII deficiency (Anwar and 
Miloszewski, 1999). 
Bleeding site Percentage 
Umbilical bleeding  80 
Superficial bruising  60 
Subcutaneous hematoma  55 
Menorrhagia 35 – 64 
Mouth and gums  30 
Intracranial haemorrhage  25-30 
Muscles  27 
Lacerations  24 
Joints  24 
After surgery  17 
Peritoneal  14 
Epistaxis  10 
Genital  9 
Renal 8 
Peripheral nerves 6 
Eye, Gastrointestinal, spleen 3 
Ears 2 
Pleural 1 
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2.4.2 Acquired FXIII deficiency 
Acquired FXIII deficiency develops through two main mechanisms: either due to the 
formation of auto-antibodies against a FXIII subunit or due to a reduction in the synthesis 
of a FXIII subunit as a result of impaired bone marrow function or liver disease, over 
consumption, or dilution coagulopathy; the latter result in a moderate FXIII deficiency.  Up 
to 2011, more than 50 cases of FXIII deficiencies due to an anti-FXIII-A autoantibody were 
reported in the literature (Muszbek et al., 2011a). In most cases, the formation of anti-FXIII 
autoantibody is idiopathic and commonly seen in elderly patients. In about 30% of the 
cases, the autoantibody develops in patients with an autoimmune disorder, especially in 
cases with systemic lupus erythematosus. Some medications have also been associated with 
acquired FXIII deficiency including isoniazid (Otis et al., 1974), penicillin (Lopaciuk et al., 
1978), phenytoin (McDevitt et al., 1972), and practolol (Milner et al., 1977). Formation of 
antibodies in cases of congenital FXIII is very rare and has been observed in few cases 
receiving frequent transfusion (Henrikson et al., 1983).  
Auto-antibodies against FXIII-A are of IgG type, either neutralising or non-neutralising. 
Neutralising FXIII-A auto-antibodies act through interfering with FXIII activation, while 
non-neutralising autoantibody work through developing an immune complex with the 
FXIII subunit, resulting in a rapid clearance of the complex through the reticulo-endothelial 
system. It was noted that most of the early reported cases of acquired FXIII deficiency were 
claimed to be due to neutralising auto-antibodies. However, this might be a result of 
difficulties in identifying non-neutralising auto-antibodies (Muszbek et al., 2011a). In a 
systematic review of patients in Japan reported with acquired FXIII deficiency, 21 patients 
were identified (13 male and eight females). In ten cases, FXIII activities were below 5 
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IU/dL. Intramuscular and subcutaneous bleeding was the most common symptom, seen in 
half of the cases (Ichinose and Souri, 2011).  
FXIII concentrate infusion has been used in patients with acquired factor XIII deficiency 
during acute bleeding with or without blood transfusion, while fresh frozen plasma and 
cryoprecipitate are less successful (Nakamura et al., 1988). Plasmapheresis might be used 
to improve the symptoms by reducing the auto-antibody level.  Some immunosuppressants, 
such as cyclophosphamide, have been used for managing cases of acquired FXIII 
deficiency by reducing the antibody concentration and improving FXIII function. The same 
therapy has been used for other hematologic disorders with an autoimmune mechanism 
such as autoimmune haemolytic anaemia, chronic immune thrombocytopenia, and acquired 
factor VIII inhibitors. Rituximab, has been rarely used in the treatment protocol to inhibit 
B-cell proliferation and cell medicated cytotoxicity (Ichinose and Souri, 2011). 
2.4.3 Diagnosis: 
The diagnosis of congenital FXIII deficiency is based on the clinical history of bleeding 
diathesis, especially delayed umbilical cord bleeding, in the presence of normal laboratory 
coagulation screening tests, such as prothrombin time (PT), activated partial thromboplastin 
time (APTT), fibrinogen level, platelet count and bleeding time. The following algorithm 
has been recommended to diagnose and classify FXIII deficiency (Karimi, 2009; Kohler et 
al., 2011): 
A- A screening test for the detection of FXIII deficiency using a quantitative FXIII 
activity assay.  
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B- If FXIII activity with the above test is found to be reduced, further tests are 
performed to detect the subtype of FXIII deficiency. These include:  
a. Measurement of plasma level of FXIII-A2B2 antigen, If FXIII-A2B2 
antigen concentration is decreased,  
b.  Measurement of FXIII activity and FXIII-A antigen in the plasma and in 
platelet lysate and measurement of FXIII-B concentration in plasma. 
C- FXIII-subunits auto-antibody assessment through: 
a. Detect neutralising antibodies against FXIII-A 
b. Binding assays to detect non-neutralizing antibodies against FXIII-A and 
FXIIIB. 
D- Evaluation of the presence of FXIII inhibitors by analysing cross-linked fibrin using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
E- Study of the molecular genetic defect. 
2.4.3.1 Non Quantitative assay – Urea clot solubility assay  
The urea clot solubility was the first test used in the investigation of FXIII deficiency and is 
still used to diagnose cases who have FXIII levels of <1%.  A survey conducted in 2002 by 
the UK National External Quality Assessment Scheme for Blood Coagulation (UK 
NEQAS) revealed that 125 out of 150 (83%) of UK laboratory centres continued to use a 
clot-solubility screening test(Jennings et al., 2003). The test involves incubating the plasma 
with thrombin with or without calcium ions until a clot is formed. The test is considered 
positive when the clots dissolve following the addition of 5 M urea, 2% acetic acid or 1% 
monochloracetic acid. The test sensitivity can vary from <0.5% to 5% FXIII activity based 
on the fibrinogen level, the solubilising agent concentration, and the clotting reagent used 
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(thrombin, Ca2+ or a combination of the two) (Jakobsen and Godal, 1974; Francis, 1980; 
Jennings et al., 2003).  A study on the sensitivity of clot solubility test recommended the 
use of a combined thrombin/acetic acid in the clot solubility test as the thrombin/acetic acid 
is sensitive to a minimum FXIII activity of 10 IU/dL compare to the calcium/urea method 
which is sensitive in detecting FXIII activity between 1 and 5 IU/dL, with an intermediate 
sensitivity for the calcium/acetic acid and thrombin/urea methods (Jennings et al., 2003).  
The test has many disadvantages as it is poorly standardised and relatively insensitive, 
detecting only severe deficiency (i.e. <5 IU/dL FXIII activity). The use of this method 
alone in screening for FXIII deficiency contributes to the underestimation of the prevalence 
of this condition because this test would be normal in mild FXIII deficiency with FXIII 
levels above 10-30 IU/dL (Mackie et al., 2013). 
2.4.3.2 Quantitative FXIII activity assays: 
Quantitative FXIII activity assays are based on activating FXIII in plasma using thrombin 
and Ca2+ , followed by the measurement of the transglutaminase activity of FXIIIa using 
two assay principles: the measurement of ammonia released during the transglutaminase 
reaction (chromogenic or ammonia release assays), and the measurement of labelled amine 
incorporated into a protein substrate (amine incorporation assays) (Karimi, 2009). 
2.4.3.2.1 Ammonia release assay: 
In the ammonia release assay, the clotting of plasma is inhibited by a fibrin polymerisation 
inhibitory peptide. FXIIIa then cross links a small molecular weight substrate amine to a 
glutamine-containing oligopeptide, and ammonia released during this transglutaminase 
reaction is measured with an NAD(P)H-dependent glutamate dehydrogenase reaction using  
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photometric method and at a wavelength of 340nm (Muszbek et al., 1985). The Berichrom 
FXIII (Siemen’s Healthcare, Marburg, Germany) and REA-chrom FXIII (Reanal, 
Budapest, Hungary) both measure FXIII activity using the ammonia release assay principle. 
The difference between the two assays is in the cofactor used, which is NADH in the 
Berichrom FXIII assay, while REA-chrom FXIII uses NADPH as a cofactor for the 
indicator reaction (Ajzner and Muszbek, 2004). The advantage of ammonia release assays 
is that they are true kinetic assays and can be easily automated and performed in one step 
using single reagent, in addition to being rapid, taking less than 10 minutes to produce 
results. Their disadvantage is the relatively low sensitivity, as they fail to give measurable 
results when FXIII is less than 5% for the Berichrom FXIII, or less than 3% for the REA-
chrom FXIII assay (Karimi, 2009). The specificity of FXIII activity assays can be affected 
by the presence of some side-reactions that result in the release of ammonia or the 
consumption of NADPH independent of FXIIIa activity, with 2-15 % overestimation of 
FXIII activity. For this reason, plasma blank solution are recommended to  be measured 
and their value is subtracted from the test plasma readings to obtain correct FXIII activity 
results and prevent systematic overestimation (Ajzner and Muszbek, 2004). A plasma blank 
is provided with the REA-chrom FXIII kit or prepared by the user of Berichrom FXIII. 
2.4.3.2.2 Amine incorporation assays 
The amine incorporation assays are based on the formation of a covalent bond between a 
labelled amine and a glutamine residue in a protein substrate by FXIIIa. Following the 
termination of the reaction, the unbound amines are removed, leaving the protein-linked 
fraction to be measured quantitatively. The amine incorporation method has a high 
sensitivity when compared with the ammonia released assays. However, they are more time 
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consuming, difficult to standardize, and the separation step makes it unlikely to perform a 
true kinetic assay (Karimi, 2009; Kohler et al., 2011).  The Pefakit FXIII incorporation 
assay (Pentapharm, Basle, Switzerland) is a commercially available kit that measures the 
initial stage of FXIII transglutaminase activity based on the incorporation of 5-
biotinamidopentylamine into surface-adsorbed fibrinogen (Kohler et al., 1998; Wilmer et 
al., 2001).  
Using a low thrombin concentration of 1U/mL, the Pefakit FXIII assay produces a partial 
activation of plasma FXIII and can detect differences in the rate of FXIII activation in cases 
with FXIII-A Val34 to Leu polymorphism. When using the Pefakit FXIII assay, each 
genotype would have a different activation rate and subsequently different FXIII activity 
readings. The Leu34 variant in homozygote individuals is activated significantly faster 
(151- 483%) than the heterozygous (97 -251%) and Val34 wild-type individuals (46 - 
200%). A  disadvantage of this assay is that it correlates poorly with the antigenic assay 
(Karimi, 2009; Kohler et al., 2011). 
The FXIII Standardization Working Party of the ISTH Scientific and Standardization 
Committee (SSC) considered the establishment of a reference material with a standard 
potency for both FXIII activity and antigen and thus reduces the variations between 
different laboratories and help in unifying their results. For this purpose, the SSC developed 
the World Health Organisation (WHO) reference plasma with an assigned FXIII activity 
and FXIII-A2B2 antigen values in International Units to be the 1st International Standard 
for Factor XIII, Plasma (IS). The WHO reference plasma is available from the National 
Institute of Biological Standards (NIBS) (Potters bar, UK) to be used for the calibration of 
reference plasmas by companies manufacturing FXIII assay kits (Raut et al., 2007). 
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An abnormal level of FXIII of 1% or less using a clot solubility test has been correlated 
with delayed umbilical bleeding and has a high risk of ICH in the first decade of life (Hsieh 
and Nugent, 2008). However, it is still difficult to correlate FXIII activity with the severity 
of other bleeding symptoms because the limitations of methods to accurately detect < 5% 
FXIII activity. Therefore, more sensitive assays of FXIII activity are required in order to 
determine which patients are at highest risk of bleeding based on their FXIII level (Hsieh 
and Nugent, 2008; Muszbek et al., 2011a). 
2.4.3.2.3 Fluorometric FXIII assay:   
This is based on the isopeptidase activity of human plasma FXIII and useful in detecting 
plasma FXIII activity < 5 IU/dL. In this method, the increase in emission resulting from an 
N-terminal attached fluorophore is observed continuously. An internally attached dark 
quencher is hydrolysed from a substrate peptide via the isopeptidase activity of FXIIIa. 
This method allows measurement of FXIIIa activity in a kinetic mode over a broad range of 
time and concentrations without reduction of the substrate. In comparison to the 
photometric assay, the fluorometric assay was found to be suitable for determining plasma 
FXIII levels in healthy individuals (Oertel et al., 2007). 
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2.4.3.3 FXIII Ag assays: 
FXIII Antigen assays are needed for the purpose of classifying FXIII deficiencies. One 
method involve using ELISA test, such as R-ELISA FXIII (Reanal-ker, Budapest, 
Hungary). This example consists of a one-step ELISA test for detecting complexed FXIII in 
diluted plasma using horseradish peroxidase labelled monoclonal antibody detector against 
FXIII-A, and biotinylated monoclonal capture antibody to detect FXIII-B (Katona et al., 
2000). The test is considered highly sensitive, with an ability to determine FXIII levels 
from 0.1% and above, making it a test of choice in determining FXIII traces among patients 
with homozygous FXIII deficiency. In addition, R-ELISA FXIII is useful for monitoring 
plasma FXIII concentration following replacement therapy with FXIII concentrates, with a 
reference interval of 14.0 to 28.0 mg/L, or 69 to 133% of normal average plasma FXIII 
concentration, based on the guidelines of the National Committee for Clinical Laboratory 
Standards (NCCLS).  
Another immunoassay method for determining FXIII-A and B antigen level relies on latex-
enhanced immune precipitation (Instrumentation Laboratory, Milano, Italy). The main aim 
of immunoassay methods is to obtain identical results with noncomplexed FXIII-A and 
with FXIII-A in complex with FXIII-B and that binding of FXIII to fibrinogen had no 
influence on the assay results (Katona et al., 2000; Katona E et al., 2001). 
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2.4.4 Treatment of Factor XIII deficiency 
2.4.4.1.1 Treatment products 
The early cases of FXIII deficiency were treated using whole blood, cryoprecipitate and 
fresh frozen plasma (FFP) as a source of FXIII.  Since the half life of endogenous FXIII is 
long, ranging from 5 to 11 days, prophylactic therapy has been given in form of FFP doses 
of 10 mL kg-1 every 4 to 6 weeks and cryoprecipitate in doses of one bag per 10–20 kg 
every 3 to 4 weeks . However, these therapies are associated with a risk of blood born 
diseases such as hepatitis, HIV, West Nile virus and other viruses and it is recommended 
that treatment should be, when possible, with FXIII concentrates (Gootenberg, 1998; Hsieh 
and Nugent, 2008). 
Taking advantage of the high concentration of FXIII in placental tissue (10 folds greater 
than the plasma level), the first placenta-derived FXIII concentrate was developed in 1970 
with a similar half life to plasma FXIII, but it only contained FXIII-A2 homodimer without 
FXIII-B. The recommended dose was10 IU/kg body weight per month for type II 
congenital FXIII deficiency, and higher doses (about 15 IU/kg body weight) were needed 
for patients with type I FXIII deficiency since the infused FXIII transamidase activity was 
lower in this group of patients (Rodeghiero et al., 1991). However, its use was decreased in 
1992 following the availability of plasma FXIII concentrate. 
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2.4.4.1.1.1 Plasma Factor XIII concentrates 
Plasma FXIII concentrate (Fibrogammin P; Dade Behring, Marburg, Germany) combine 
both FXIII-A and FXIII-B subunits. This concentrate was developed in the 1980s. It is a 
highly purified, heat-treated, lyophilised preparation and obtained from a human FFP after 
being tested and found negative for hepatitis, HIV, and high levels of alanine amino-
transaminase. Fibrogammin P is usually provided as a freeze-dried powder stored in vials 
containing 1250 units that is equal to the amount of FXIII obtained from 1250 ml of plasma 
(Gootenberg, 1998).  
The first multicentre prospective study on Fibrogammin P was conducted in France and 
involved 16 patients with male to female ratio of 3:1 and aged from 2 weeks to 46 years on 
regular infusions over variable periods ranging from19–108 weeks. The study reported a 
good tolerance toward the therapy with no detectable anti FXIII inhibitors. There was no 
reported major bleeding episode. Two patients reported some side effects in form of 
headache during menstrual cycle and a transient urticarial reaction (Dreyfus et al., 2003).   
A more recent ongoing study on Fibrogammin P in the United States included 61 patients, 
male to female ratio of 3:1 and a mean age of 12.7 years (ranging from 1 to 74 years).  
Patients who received monthly prophylaxis of Fibrogammin P for a period ranging from 
9.5 to 121 months had a favourable response with no development of inhibitors or 
seroconversion. The patients experienced no bleeding episode while being under 
prophylaxis, including a woman who had an uneventful pregnancy while receiving 
Fibrogammin P every three week (Nugent, 2006; Lusher et al., 2010). Furthermore, 
Castaman et al  reported six patients with FXIII deficiency with no adverse effects 
following the administration of more than 1,200 prophylactic infusions of FXIII 
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concentrate in a dose 10 IU/kg per month during a maximum period of 20 years (Castaman, 
2008). Therefore, Fibrogammin P is considered to be a convenient source of FXIII for 
patients with FXIII deficiency with an ability to produce normal clotting pattern according 
to thromboelastography (Nugent, 2006; Lusher et al., 2010; Dreyfus et al., 2011).  
Currently, the product is approved for use in the treatment of patients with FXIII deficiency 
in several countries including UK, Japan, and Germany and was only approved by the Food 
and Drug Agency (FDA) to be used in the U.S in 2011(Behring CSL, 2011). It is 
recommended by the manufacturer to be administered every 4 to 6 weeks at a dose of 
10U/kg for prophylaxis against bleeding, and up to 35 U/kg prior to surgical procedures 
(Behring CSL, 2011). Fibrogammin P dosage can vary widely according to patient 
response and pharmacokinetics. This variation can be attributed to the heterogeneity of 
FXIII deficient patients, the presence or absence of intracellular FXIII subunits, and the 
existence of polymorphisms that can alter FXIII activity (Hsieh and Nugent, 2008). 
2.4.4.1.1.2 Recombinant Factor XIII concentrates 
The recombinant FXIII-A2 (rFXIII-A2) homodimer is developed in Saccharomyces 
cerevesiae and contain no human or mammalian products in the culture or media. 
Following administration of rFXIII-A2, the rFXIII-A2 homodimers rapidly combine with 
free plasma FXIII-B subunit to form stable FXIII-A2B2 heterotetramer with a terminal half 
life of 9 to 13 days. The first recombinant FXIII concentrate was developed in the early 
1990s (ZymoGenetics Incorporated, Seattle, Washington) but was not tested in any clinical 
trial. In 2005, a study of the safety and pharmacokinetic of rFXIII-A2 administered to 50 
healthy volunteers using a dose range from 25 to 50U/kg found an increase in the rFXIII-
A2 plasma activity to 64-88% above baseline (Reynolds et al., 2005; Visich et al., 2005).  
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This was followed by a phase one clinical study of the drug pharmacokinetic and safety 
profile using a single dose rFXIII-A2 in 10 adults affected with congenital FXIII-A 
deficiency.  The patients in the study had an increase in their FXIII plasma activity of 57 to 
59 IU/dL, 105 to 129 IU/dL, and 160 to 181 IU/dL following the administration of 20 U/kg, 
50 U/kg, and 75 U/kg rFXIII respectively, with a median dose response of 2.4% increase in 
FXIII activity for every unit of rFXIII given per kilogram body weight. Furthermore, the 
stable FXIII-A2 B2 formed as a result of rFXIII administration in this study had a half life 
of 8.5 days similar to that of endogenous plasma FXIII, with no adverse effects or antibody 
formation against rFXIII. However, rFXIII concentrate administered to patient with FXIII-
B subunit deficiency had a shortened terminal half-life of 8.9 hours, and an increased 
clearance compared with the patients with FXIII-A2 deficiency (Lovejoy et al., 2006).   
2.4.4.1.2 Treatment of acute bleeding 
For the management of acute bleeding in patients with FXIII deficiency, treatment with 
FXIII concentrate is recommended in a dose of 10–20 units per kilogram body weight. 
Regular monitoring of plasma levels is important to maintain plasma FXIII levels above 
10-20 IU/dL until the bleeding is controlled. 
2.4.4.1.3 Regular Prophylaxis  
Prophylactic factor replacement is mandatory in patients with FXIII deficiency and 
previous history of ICH. Prophylactic therapy is also recommended to patients with severe 
FXIII deficiency (FXIII level <1 IU/dL) and considered in those patients with FXIII level 
<4 IU/dl (Anwar et al., 2002; Bolton Maggs et al., 2004).  Castaman suggested that FXIII 
level of 5 IU/dL is sufficient to prevent spontaneous bleeding (Castaman, 2008). It was also 
55 
 
recommended that maintaining plasma FXIII level of 3-10 IU/dL is required to prevent life 
threatening bleeding such as spontaneous ICH (Anwar et al., 2002). The United Kingdom 
Haemophilia Centre Doctors' Organisation (UKHCDO) in its latest (2004) guidelines 
recommend FXIII concentrate in a dose of  10 units /kg body weight at 4 weekly intervals 
to provide adequate prophylaxis for patients with severe  FXIII deficiency(Bolton Maggs et 
al., 2004).  
2.4.4.1.4 Prophylaxis during surgery 
Surgery and other invasive procedures can be managed by providing sufficient amount of 
replacement therapy prior and during the procedure using FXIII concentrate or, if 
concentrate is not available, large amounts of FFP.  In a major surgery, a daily dose of 20–
30 U per kilogram body weight is recommended shortly before the operation, while for a 
minor surgery, a daily dose of 10-20 U per kilogram body weight is needed. Following the 
surgery, the plasma FXIII level is monitored, aiming to achieve FXIII level above 5 IU/dL 
for 5 days after the surgery or until the wound has healed completely (Bolton Maggs et al., 
2004). However, there are no prospective or controlled trials to validate the recommended 
FXIII level needed in these settings. 
2.4.4.1.5 Prophylaxis during pregnancy and labour 
Pregnant women with FXIII deficiency can develop deicidual bleeding as early as the 5th or 
6th week of gestation resulting in miscarriage unless prevented using replacement therapy. 
The aim of the perinatal management is to keep FXIII-A levels higher than 10 IU/dL, or at 
least 2-3 IU/dL to avoid miscarriage (Asahina et al., 2007). The UKHCDO   recommended   
regular prophylaxis in pregnancy with   monitoring plasma FXIII level, aiming to keep the 
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trough level >3 IU/dL. For this purpose, FXIII concentrate is the treatment of choice rather 
than FFP or cryoprecipitate (Bolton Maggs et al., 2004).  
FXIII concentrate is recommended to be administered in a dose of 250 U weekly during the 
first 22 weeks of gestation and to be increased to 500 IU weekly from 23 weeks of 
pregnancy onward. The aim of the treatment is to maintain FXIII-A levels above 10-20 
IU/dL throughout pregnancy (Asahina et al., 2007; Peyvandi et al., 2011a). Meanwhile, 
during labour, a dose of 1000 U of FXIII concentrate has been recommended to achieve a 
level greater than 20-30 IU/dL needed to prevent extensive obstetrical bleeding, including 
primary postpartum haemorrhage (PPH) and wound bleeding. Administration of FXIII 
concentrate during labour would also reduce the chance of developing secondary PPH 
considering the long half life of plasma FXIII (Ichinose et al., 2005; Hsieh and Nugent, 
2008). 
2.4.5 Obstetric and gynaecological manifestation of FXIII deficiency  
2.4.5.1  Menstrual cycle 
The histology of the uterus consists of endometrium, myometrium and perimetrium. The 
endometrium forms the inner layer of uterus and is made of a specialised mucosal layer 
comprising a basal and superficial layer of glandular epithelium as well as cellular stroma. 
It is constantly undergoing cyclical changes in form of growth, differentiation and finally 
cyclical shedding leading to menstruation, all in response to changes in the sex hormone 
throughout a woman’s reproductive life (Fusi et al., 2006). 
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The first day of the menstrual cycle begins with the initiation of menstrual flow. The 
menstrual phase, lasting usually between 4 to 6 days, is characterised by the shedding of the 
thickened endometrium to form menstrual bleeding. Days 7 through 14 represent the 
follicular or proliferative phase, which conclude in ovulation. The luteal, or secretory phase 
lies between days 15 and 28 (Farage et al., 2009). The follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH), both secreted from the pituitary, play an important role in 
the morphological changes in the ovaries and uterus during menstruation. Following 
menstruation, LH together with follicle-stimulating hormone initiates production of several 
primary follicles, which produce estradiol as well as other estrogens, leading to an increase 
of endometrial thickness. The estradiol level starts to steeply increase about a week before 
ovulation, reaching its maximum one day before the LH peak (one day before ovulation), 
followed by a rapid decline. After ovulation, the corpus luteum is formed in the ovaries 
which produce progesterone in increasing amounts, rising up to 10 fold during the week 
following ovulation and making it the dominant hormone during the early and mid-luteal 
phase. As the luteal phase progresses, estradiol rises again, reaching a second peak 5-7 days 
after ovulation. Decreasing levels of estradiol and progesterone in the late luteal phase 
result in endometrial breakdown and, eventually, menstruation (Muizzuddin et al., 2005). 
Normal menstrual cycle begins at 11–14 years of age, with a normal cycle interval is 21–
45 days, and the normal length of menstrual flow is seven days or less with an average 
cycle requiring no more than 3–6 pads or tampons per day (Diaz et al., 2006). Normal 
menstruation does include a haemostatic process involving primary platelet aggregation 
followed by secondary fibrin formation as well as fibrin clot modelling through 
fibrinolysis. Any deviation from this process can result in menorrhagia (Kouides and Kadir, 
2007) (Figure 2.5).   
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Figure  2.5 Pathophysiology of homeostasis during menstrual cycle leading to 
menorrhagia(129) 
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2.4.5.2 Assessment of menstrual blood loss 
Menstruation and ovulation may be accompanied by significant bleeding resulting in 
limitation in performing daily activities as well as adverse effect on social functioning and 
quality of life. Menorrhagia is defined as a complaint of heavy cyclical menstrual bleeding 
occurring over several consecutive cycles (Royal College of Obstetricians and 
Gynaecologists, 1998). An objective definition of menorrhagia is menstrual bleeding of 
80 ml or greater per menstruation (Hallberg et al., 1966).  
Menstrual blood loss can be assessed using pictorial blood-assessment chart (PBAC) that 
relies on visual assessment and scoring of sanitary pad and tampon saturation (Higham et 
al., 1990). This method was developed in an attempt to create a simple non laboratory 
method of assessing menstrual blood loss that is more accurate than other simple methods 
such as tampon and pad counting and the weighing of such blood-stained materials. In 
addition to recording the number of the towels and tampons used, the degree to which 
individual items are soiled is also taken into consideration. In this method, women use 
special sheet to document the number of sanitary pads and/or tampons used each day (24 
hour) based on the degree of saturation of the pads/tampons, and record the number and 
size of blood clots if present (Appendix 4).  The total score are calculated by adding up the 
pad/tampons counts obtained from each day of the period.  The scores assigned for tampons 
were “1” for each lightly stained tampon, “5” if moderately stained and “10” if it was 
completely saturated with blood. The towels were given ascending scores of “1”, “5” and 
“20”.  Small and large clots scored “1” and “5”, respectively. PBAC score ≥ 100 were 
considered a heavy menstrual bleeding equivalent to more than 80 ml blood loss. The chart 
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was found to have a sensitivity of 86% and a specificity of 89%, using scores used by the 
women. The sensitivity and specificity were 86% and 81%, respectively, using the 
gynaecologist’s score (Higham et al., 1990). The test was shown to be an accurate tool in 
measuring menstrual blood loss (Zakherah et al., 2011). 
 
2.4.5.3 Menorrhagia  
Menorrhagia is a common gynaecological problem and result in seeking medical attention 
in 5–10% of women of reproductive age (Oehler and Rees, 2003). Causes of menorrhagia 
can vary from organic, anatomical and endocrine. Organic causes include genitourinary 
infections or organic dysfunction as hepatic or renal failure. Abnormal liver function will 
affect the synethesis of the clotting factors and impair hormone metabolism such as 
oestrogen. Abnormal endocrine fuction can lead to menorrhagia, especially anovulatory 
dysfunctional uterine bleeding among adolescent females due to immature hypothalamic–
pituitary–ovarian axis. Anatomic causes for menorrhagia include uterine fibroids, 
endometrial polyps and hyperplasia. Other causes of increased menstrual bleeding include: 
the Intra Uterine Contraceptive Device (IUCD), corticosteroids, anticoagulants and 
chemotherapy (Warner et al., 2004).  
Despite all the known causes of menorrhagia mentioned above, around 50% of those with 
objective menorrhagia had no uterine pathology when they were examined following 
hysterectomy for non-malignant reasons (Clarke et al., 1995). For such groups it is 
important to search for underlying bleeding disorders that can be presented as menorrhagia. 
Previous studies have found inherited bleeding disorders, mainly von Willebrand Disease 
(VWD),  in 17% of patients with menorrhagia when defined by PBAC score more than 100 
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(Kadir et al., 1998), 20% of menorrhagia when defined based on the amount of blood loss 
(Edlund et al., 1996), and 10.7% of menorrhagia based on medical records (Dilley et al., 
2001) . The prevalence of menorrhagia among women with bleeding disorders can vary 
based on the disease type, from 74% among women with VWD to 57% among carriers of 
haemophilia and 59% among women with factor XI deficiency (Kadir et al., 1999b).  The 
mechanism of menorrhagia in women affected by bleeding disorders might be related to a 
defect in the formation of a platelet plug that is an important phase in regulating menstrual 
blood flow (Christiaens, 1996). 
Diagnosis of menorrhagia have been an important element in the evaluation of women 
referred for the possible diagnosis of bleeding disorder and thus was incorporated into the 
bleeding score assessment system designed through the ISTH (Rodeghiero et al., 2010; 
Rydz and James, 2012).  
Menorrhagia due to bleeding disorder is expected when there is a prolonged menstrual 
bleeding more than seven days duration, menstrual bleeding per cycle more than 80 ml, 
soaking one pad or tampon per hour, producing clots larger than one inch in diameter, 
blood soaked onto clothes or bed, or PBAC score of more than 100 or 150 (James, 2009; 
Zakherah et al., 2011).  Those with a significant history of menstrual bleeding should be 
further screened for coagulation tests including complete blood count, PT, APTT, thrombin 
time, Von willebrand factor (VWF) antigen, factor VIII levels, platelet function analyses 
and FXIII level. 
The initial step in the management of menorrhagia in women with bleeding disorders is 
through conservative or medical therapy in the form of hormonal therapy, such as 
combined oral contraceptive pills, or haemostatic therapy including antifibrinolytic 
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(tranexamic acid and aminocaproic acid) and DDAVP or desmopressin, as well as 
replacement therapy with coagulation factors (Peyvandi et al., 2011b). Surgical 
management may be required in some cases, especially haemophilia carriers, and treatment 
varies from levonorgestrel-releasing IUD, endometrial ablation or hysterectomy (Sanders et 
al., 2012). 
2.4.5.4 Ovulation bleeding: 
Women with bleeding disorders are at risk of bleeding from ruptured ovarian follicles. At 
the time of ovulation, an ovum extruded from the follicle on the surface of the ovary into 
the peritoneal cavity. Usually, this process is not associated with significant bleeding 
(Reproductive endocrinology, 2001). However, women with bleeding disorders may have a 
higher amount of bleeding that presents in various forms; either into the peritoneal cavity in 
the form of mid cycle vaginal bleeding or pain (Mittelschmerz sign); bleeding to the 
residual follicle (the corpus luteum) resulting in a haemorrhagic ovarian cyst; or bleeding 
into the uterine broad ligament resulting in a retroperitoneal haematoma. Mittelschmerz 
sign in rare bleeding disorders was reported in a survey on 81 menstruating women with 
type 1 VWD were 49% reported mid-cycle pain (Kouides et al., 2000).  
Haemorrhagic ovarian cysts, while less common than menorrhagia, have been observed in 
many case reports of involving women with bleeding disorders. In a case series of 136 
women with VWD, nine (6.8%) had haemorrhagic ovarian cysts (Silwer, 1973). Lak et al 
reported a case series of women with FXIII deficiency, and four out of 20 women (20%) 
experienced ovarian bleeding, requiring hysterectomy in one of the cases (Lak et al., 2003). 
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The importance of recognising rare bleeding disorders in patients with haemorrhagic 
ovarian cysts lies in the need of providing adequate prophylaxis prior to surgical treatment 
of ovarian cysts and intra-abdominal bleeding, or manage those patients through non-
surgical approach when possible. Oral contraceptives pills (OCP) have been used as a 
prophylaxis against the development of this type of bleeding by preventing ovulation 
(Payne et al., 2007). 
2.4.5.5 Miscarriage 
Recurrent miscarriage is defined as spontaneous loss of three or more consecutive 
pregnancies occurring before week 20 of pregnancy, and it affects 1% of women of 
reproductive age while the loss of two or more consecutive pregnancies affects 
approximately 5% of women (Rai and Regan, 2006). Recurrent miscarriage is attributed to 
various causes ranging from anatomical, genetic, infectious, endocrine, immune, and 
idiopathic.  In a recent study on the aetiology of recurrent miscarriage, abnormal embryonic 
karyotype was considered the most common causes of recurrent miscarriages in their study 
cohort (Sugiura-Ogasawara et al., 2012).  The risk of miscarriage is double when at least 
one member of a couple is a carrier of chromosomal anomalies. Therefore, karyotyping of 
both couples is a standard investigation for cases with recurrent miscarriage. The maternal 
age may also be a risk factor as there is an observed trends toward increased unbalanced 
structural anomalies in younger mothers and decreased viable autosomal trisomies in the 
older women (Grande et al., 2012).  Uterine anatomical abnormalities are also within the 
common cause of miscarriages, mainly septate, bicornuate and didelphic uterus. Cervical 
anomalies due to damage from birth trauma or surgical intervention may also contribute 
into the aetiology of repeated pregnancy loss (Porcu et al., 2000).  Endocrine anomalies are 
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strongly related to recurrent miscarriages such as thyroid dysfunction, thyroid 
autoimmunity (Abalovich et al., 2002), polycystic ovarian syndrome (Homburg, 2008), and 
type one diabetes mellitus (Christiansen et al., 2008).  Miscarriage can also be the outcome 
of atypical humoral or cellular immunological responses towards the embryo. 
Thrombophilia, both inherited and acquired, have been associated with risk of recurrent 
miscarriage (McNamee et al., 2012a). The most common example is antiphospholipid 
antibody syndrome seen in 15% of women with recurrent pregnancy loss and can be 
associated with a high risk of pregnancy loss up to 90% if no treatment was given during 
pregnancy (Rai et al., 1995). The mechanism of pregnancy loss in these cases were mainly 
through thrombosis of uteroplacental vasculature resulting in placental infarction, in 
addition to defect in endovascular trophoblast invasion (Sebire et al., 2002). Hereditary 
thrombophilia caused by mutations in the factor V and prothrombin gene, antithrombin as 
well as protein C and S deficiency are also known causes for recurrent miscarriages 
(Rodger et al., 2008). 
 Despite detailed evaluation, around 50% of cases are unexplained (Li et al., 2002).  This 
makes recurrent miscarriage an emotional and physical challenge for any couple who 
experience the repeated loss of their offspring together with anxiety from the idea of losing 
further pregnancies due to miscarriage. 
Pregnancy is associated with changes in the maternal coagulation and fibrinolytic system 
which is necessary for the development of uteroplacental circulation; a balance in these two 
systems is required to maintain pregnancy to prevent excessive fibrin deposition in 
placental vasculature and intravillous spaces, maintain fibrin polymerisation, and stabilise 
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the placental basal plate (Buchholz and Thaler, 2003). This has led to speculations for two 
further causes for recurrent miscarriage; haemorrhagic and thrombotic.  
Thrombotic disorders are more commonly associated with recurrent miscarriage, possibly 
through microthrombi formation in early placental vessels (Bick, 2000). These disorders 
include antiphospholipid syndrome; reduced activity of tissue plasminogen activator; 
increased PAI-1; deficiency of protein C, S; antithrombin III and heparin cofactor II(Bick 
and Hoppensteadt, 2005; Brenner, 2010).  However, except for antiphospholipid syndrome, 
the association of most other thrombophilic disorders with recurrent miscarriage needs to 
be debated as most research conducted in this area are observational or case control studies 
involving small cohort of women (McNamee et al., 2012a, 2012b). 
Bleeding disorders have also been described in small series to be associated with recurrent 
miscarriage, including prothrombin deficiency, reduced factor V, VII, X, XII and XIII, and 
afibrinogenemia (Jones et al., 2003; Bick and Hoppensteadt, 2005; Settin et al., 2011).  
Women with congenital FXIII deficiency have been known to be at risk for recurrent early 
pregnancy loss (Rodeghiero et al., 1987; Inbal and Kenet, 2003; Asahina et al., 2007), 
especially in the presence of a history of severe bleeding diathesis as delayed umbilical 
bleeding and ICH (Burrows et al., 2000; Gmez-Garca et al., 2001; Meili, 2002). A study of 
351 women with recurrent miscarriage found FXIII deficiency in one (0.3%) of the cases 
(Bick and Hoppensteadt, 2005).   
Homozygous FXIII Val34Leu polymorphisms have been suggested to be associated with a  
high risk of early pregnancy loss (Dossenbach-Glaninger et al., 2003). In addition, Anwar 
et al (Anwar et al., 1999) suggested that Tyr204Phe polymorphism was more commonly 
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seen among women with history of recurrent miscarriage; However, in a meta-analysis 
study, factor XIII Val34Leu and Tyr204Phe polymorphisms were not significantly 
associated with recurrent miscarriage (Sotiriadis et al., 2007). A more recent study of 100 
Iranian women with history of at least two pregnancy losses found a significantly high 
prevalence of Tyr204Phe and Pro564Leu polymorphism among women with recurrent 
miscarriage while Val34Leu polymorphism was not significantly related to recurrent 
pregnancy loss (Jeddi-Tehrani et al., 2010).  It is thought that FXIII may cross-link 
substrates, other than fibrin, during its role in maintaining pregnancy and that some 
heterozygous mutation may be associated with recurrent miscarriage by altering the 
structure of FXIII with no direct effect on FXIII level and activity.   
In addition, the presence of other coagulation factor polymorphisms may have a synergistic 
effect on the role of FXIII polymorphism in inducing recurrent miscarriage. PAI-1 plays a 
major role in hypofibrinolysis and thrombotic complications. The PAI-1 gene expression is 
modulated by a 4G/5G polymorphism in the promoter region (Mikkola et al., 1997). 
Studies on arterial thrombotic tissues and pulmonary emboli concluded that PAI-1 
polymorphism, when associated with FXIII Val34Leu polymorphism, can increase the risk 
of fibrinolysis impairment (Kohler, 2001). This is done through inhibiting the fibrinolytic 
system activity and increasing fibrin network resistance against fibrinolysis. Elevated  PAI-
1 concentration could result in defect in fibrinolysis and coagulation system and hence 
increase thrombosis, thus can initiate placental damage and thrombotic complication 
(Kohler, 2001). However, this was debated in a later study, comparing 63 women with 
recurrent miscarriage to a control group, and found only PAI-1- 4G polymorphism to be a 
risk factor for recurrent miscarriage, but no similar role of FXIII Val34Leu polymorphism.  
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The mechanism behind pregnancy loss in patients with FXIII deficiency is still not 
precisely known. It is believed that women with FXIII deficiency lack FXIII-A in the 
placental bed, resulting in early pregnancy loss due to poor formation of the 
cytotrophoblastic shell, and hence increasing the risk of placental detachment and eventual 
miscarriage within the first trimester (Asahina et al., 1998, 2000, 2007). 
2.4.5.6 Antepartum and Postpartum Haemorrhage 
Pregnancy and delivery represents one of the greatest haemostatic challenges to women, 
and an important cause of maternal mortality in many parts of the word. In the 2006–2008 
UK Confidential Enquires into Maternal Death, obstetric haemorrhage was the fourth most 
common cause of direct maternal death. Many of the cases reviewed were considered to 
have been avoidable and 70% were secondary to substandard care (Wilkinson and Trustees 
and Medical Advisers, 2011). The risk of obstetric bleeding in women with bleeding 
disorders has only been addressed in the past few decades, representing a serious source of 
morbidity and mortality in these group of women  due to lack of awareness for early 
diagnosis and management. 
Antepartum haemorrhage (APH) is defined as vaginal bleeding occurring from 24 weeks of 
gestation. The incidence of APH  ranges from 5.9 to 6.5 per 1000 with a very high perinatal 
mortality especially in placental abruption (119 per 1000 births) (Bhide and Thilaganathan, 
2004; Giordano et al., 2010).  
The prevalence of APH in women with FXIII deficiency is not clear. APH was observed in 
a case report of a woman with FXIII-A deficiency who experienced APH in her second 
pregnancy at 32 weeks of gestation. She was on FXIII  prophylaxis, and her pregnancy 
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progressed without adverse maternal and neonatal outcome (Gmez-Garca et al., 2001). Two 
pregnancies occurred in a woman with FXIII-A deficiency, not on prophylaxis who had 
severe APH due to placental abruption at 31st and 37th weeks of gestation (Mikkola et al., 
1997).  
Postpartum haemorrhage (PPH) is classified as primary or secondary PPH. Primary PPH is 
classically defined as a blood loss in the first 24 h after delivery with the amount of blood 
loss more than 500 mL to 1000 mL. Secondary PPH refers to excessive bleeding occurring 
between 24 h and 6 weeks post-delivery. Women with inherited bleeding disorders are at an 
increased risk of both primary and secondary PPH (Kadir et al., 2009). A large population-
based study in Norway was done using medical records of more than 300,000 pregnant 
women to determine the prevalence and risk factors for severe PPH (> 1500 mL). The 
results found VWD, one of the common bleeding disorders, to be the second most common 
cause of severe PPH and second only to emergency caesarean delivery (Al-Zirqi et al., 
2008). PPH have also been observed in few case reports and series of women with FXIII –
A deficiency (Saito et al., 1990; Burrows et al., 2000; Ivaskevicius et al., 2010b) and FXIII-
B deficiency (Ivaskevicius et al., 2010b).   
Risk of PPH in women with FXIII deficiency can be reduced through three main 
approaches; providing prophylactic treatment to maintain stable haemostatic status, 
prevention and early management of uterine atony and delivery with minimal genital 
trauma. Prophylactic replacement therapy is given for at least 3–5 days after vaginal 
delivery or 5–7 days following caesarean section to maintain the required amount of 
clotting factor level and prevent primary and secondary PPH. The use of oral tranexamic 
acid for 3–4 days post vaginal delivery or 7–10 days following caesarean section can also 
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be considered in some cases. However, this should be balanced against the risk of 
thrombosis associated with replacement therapy. Active management of third stage of 
labour using uterotonic agents had significantly reduced the incidence of uterine atony, a 
common cause of PPH (Begley et al., 1996). In case of PPH, an initial assessment and 
restoration of circulatory volume is needed either with fluid or blood transfusion, local 
causes should be excluded and replacement of the deficient clotting factor with monitoring 
of the factor levels should be performed in collaboration with haematologists (Kadir et al., 
2009). 
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3 CHAPTER THREE:  CONGENITAL FACTOR XIII DEFICIENCY 
IN WOMEN; A SYSTEMATIC REVIEW OF LITERATURE 
3.1 Introduction: 
The first clinical report of FXIII deficiency was described in 1960 (Duckert et al., 1960); 
since then, more than 500 cases of FXIII deficiency have been identified worldwide with an 
incidence of one individual in 1-3 million (Ivaskevicius et al., 2007a; Muszbek et al., 
2011a). Congenital FXIII deficiency is characterised by severe delayed spontaneous 
bleeding with normal coagulation screening tests.  
Women are more vulnerable to manifest a bleeding disorder because they are at high risk to 
experience bleeding challenges during menstruation and child bearing. Women with FXIII 
deficiency often fail to produce the same levels of clotting factors as normal women, 
making them vulnerable to bleeding diathesis, delayed wound healing and adverse 
pregnancy outcome, mainly miscarriage. 
Being a very rare condition, assessment for FXIII deficiency is not part of the routine 
evaluation tests for miscarriage unless there is a strong history of severe bleeding. Asahina 
et al, studied a case of FXIII deficiency with miscarriage and linked deficiency of FXIII 
with early pregnancy loss and implantation failure due to insufficient formation of 
extravillous cytotrophoblast (Asahina et al., 2000). For such women FXIII concentrate is 
the treatment of choice, either plasma-derived or recombinant when available. It is 
important to give the proper amount of FXIII concentrate with treatment intervals to 
achieve normal levels of FXIII during the gestational period (Asahina et al., 2007). 
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However, it is still unclear how to choose the minimum plasma level of FXIII needed to 
maintain pregnancy and prevent bleeding complications. Different guidelines provide 
different recommendations regarding the dose and interval of FXIII concentrate 
administered during pregnancy and labour and the level above which FXIII should be 
maintained to avoid adverse pregnancy outcome (Rodeghiero et al., 1987; Boda et al., 
1989; Asahina et al., 2000, 2007; Burrows et al., 2000).  
There is a paucity of data in the literature about women affected with FXIII deficiency due 
to the rarity this disorder.  This systematic review explores the existing literature to include 
case reports and case series examining the obstetrics and gynaecological outcome in 
women with congenital FXIII deficiency. 
3.2 Materials and Methods 
3.2.1 Search strategy and inclusion criteria: 
 An electronic search was performed to identify the published literature on PUBMED, 
MEDLINE, EMBASE, Journals @OVID and CINAHL Plus databases using the following 
keyword combination: ‘congenital factor XIII deficiency’ AND ‘women OR Pregnancy’. 
The bibliographic references of all retrieved studies were further assessed for additional 
sources of clinical studies.  
There were no time or language restrictions but clinical studies were only considered 
suitable if they were related to reproductive age women with factor XIII deficiency. FXIII 
deficiency was included if women had haemorrhagic diathesis (e.g. umbilical cord bleeding 
or intracranial haemorrhage) with or without a history of abnormal gynaecologic or 
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obstetric outcome and in the presence of abnormal clot-solubility test or abnormal FXIII 
quantitative assay ( FXIII activity < 70 IU/dL).  
3.2.2 Study selection: 
 The initial search revealed 933 potentially relevant articles and the full selection process is 
presented in a flow diagram (Figure 3.1). After excluding articles on grounds of duplication 
and irrelevance to women or the lack of enough data on the course and outcome of the 
cases, 39 articles were included in this systematic review. These were 27 case reports 
(Ikkala et al., 1964; Fisher et al., 1966; Hamer and Rae, 1971; Girolami et al., 1986, 1977; 
Rodeghiero et al., 1987; Capellato et al., 1987; Boda et al., 1989; Kobayashi et al., 1990; 
Saito et al., 1990; Mikkola et al., 1997; Asahina et al., 1998, 2000; Cerenzia et al., 1999; 
Burrows et al., 2000; Gmez-Garca et al., 2001; Koseki et al., 2001; Meili, 2002; 
Padmanabhan et al., 2004; Rott et al., 2004; Lovejoy et al., 2006; Takahashi et al., 2007; 
Melo, 2008; Singh et al., 2008; Dargaud et al., 2008; Hanke et al., 2010; Chakravarty et al., 
2012) and 12 case series (Burrows et al., 2000; Lak et al., 2003; Peyvandi et al., 2004; 
Bhattacharya et al., 2005; Medhaffar et al., 2006; Schroeder et al., 2007; Ivaskevicius et al., 
2007b, 2010a, 2010b; Vijapurkar et al., 2009; Ichinose, 2012; Naderi et al., 2012) dating 
from 1964 to 2012. The papers were written in English, except five written in Spanish 
(Melo, 2008), Dutch (Meili, 2002), Italian (Cerenzia et al., 1999), Japanese (Takahashi et 
al., 2007), and French (Medhaffar et al., 2006).  
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 (Factor XIII deficiency OR Congenital Factor XIII  deficiency) 
AND 
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Medline 
70 
Embase 
41 
Journals @OVID 
216 
CINAHL Plus 
1 
Pubmed 
605 
933 
702 
231 Duplicates 
632 excluded based on 
the title/ abstract   
70 
39 
31 excluded after 
reading through the text   
Figure  3.1 Flow diagram of study selection 
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3.2.3 Data extraction:  
The following data were extracted: Author and year of publication; age at the time of 
reporting and age at diagnosis; the country of origin; gravidity and parity; history of 
bleeding episodes, including menorrhagia, and treatment received. For each pregnancy the 
following data were collected; bleeding during pregnancy and gestational age at the time of 
bleeding, miscarriage and gestational age at time of miscarriage, prophylactic treatment 
prior to and/or during pregnancy; mode of delivery; gestational age at delivery, presence of 
antenatal complications; occurrence of postpartum haemorrhage; other postpartum 
complications; and neonatal outcome. 
3.3 Results: 
A total of 121 women were identified from 39 articles. There were 27 case reports 
including 30 women (Appendix 1), and 12 case series including 104 women (Appendix 2). 
Two case series (Burrows et al., 2000; Ichinose, 2012) included 13 women who were also 
reported individually as case reports (Ikkala et al., 1964; Fisher et al., 1966; Hamer and 
Rae, 1971; Girolami et al., 1977, 1986; Capellato et al., 1987; Rodeghiero et al., 1987; 
Boda et al., 1989; Saito et al., 1990; Kobayashi et al., 1990; Koseki et al., 2001; Lovejoy et 
al., 2006). These 13 cases were included only once, making the total number of women in 
the review 121 women. Demographic and clinical data are presented in Table 3.1 and Table 
 3.2 while the bleeding symptoms in the case reports are in Appendix 3. FXIII-A deficiency 
was reported in 104 women and FXIII-B deficiency in 17 women. Table  3.3 presents a 
comparison of gynaecological bleeding and pregnancy outcome between women with 
FXIII-A and B deficiencies.  
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Table  3.1 Demographic and clinical variables of 121 women (192 pregnancies) with 
FXIII deficiency. 
 Variables  References 
Age at time of case report, years ; 
median (range) 
30 (13-52)  
Age at diagnosis, years ; median 
(range) 
18 (0.5-35) (Ikkala et al., 1964; Fisher et al., 1966; 
Saito et al., 1990; Padmanabhan et al., 
2004; Melo, 2008; Ivaskevicius et al., 
2010a, 2010b) 
Consanguinity, n (%) 16/66 (24) (Ikkala et al., 1964; Fisher et al., 1966; 
Saito et al., 1990; Padmanabhan et al., 
2004; Melo, 2008; Ivaskevicius et al., 
2010a, 2010b) 
FXIII-A deficiency, n (%) 
 
104 (86)  
FXIII-B deficiency, n (%) 17 (14)   (Girolami et al., 1977; Capellato et 
al., 1987; Saito et al., 1990; Burrows et 
al., 2000; Koseki et al., 2001; Rott et 
al., 2004; Lovejoy et al., 2006; 
Ivaskevicius et al., 2010b)    
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Table  3.2 Factor XIII activities and laboratory methods reported in the literature 
review 
Variable No (%) References 
FXIII activity <5 IU/dL, n (%) 64 (53) (Ikkala et al., 1964; Girolami et al., 
1977; Rodeghiero et al., 1987; Boda et 
al., 1989; Mikkola et al., 1997; 
Burrows et al., 2000; Gmez-Garca et 
al., 2001; Meili, 2002; Lak et al., 
2003; Medhaffar et al., 2006; 
Ivaskevicius et al., 2007b; Dargaud et 
al., 2008; Vijapurkar et al., 2009; 
Naderi et al., 2012; Chakravarty et al., 
2012) 
FXIII 6-20 IU/ dL, n (%)  10 (8) (Girolami et al., 1986; Capellato et al., 
1987; Kobayashi et al., 1990; Asahina 
et al., 1998, 2000; Koseki et al., 2001; 
Peyvandi et al., 2004; Rott et al., 2004; 
Lovejoy et al., 2006; Dargaud et al., 
2008)  
FXIII 40-60 IU/ dL, n (%) 17 (14)  (Hanke et al., 2010; Ivaskevicius et al., 
2010a) 
FXIII activity not reported, n (%) 30 (25)  
Laboratory methods used for 
diagnosis of  FXIII deficiency. 
• Urea clot solubility, n (%) 
• Immunoassays of FXIII A and 
B subunit, n (%) 
• Amonia release assay, n (%) 
• Genotype analysis, n (%) 
• Not specified, n (%) 
 
 
30 (25) 
42 (35) 
 
4 (3) 
40 (33) 
5 (4) 
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Table  3.3 Comparison of gynaecological bleeding and pregnancy outcome between 
women with FXIII-A and B deficiencies 
Obstetric and 
Gynaecological bleeding 
symptoms 
FXIII-B subunit deficiency 
( 17 women, 13 pregnancies) 
FXIII-A subunit deficiency 
(104 women, 179 pregnancies) 
Menorrhagia 4/17 (13%) 27/104 (26%) 
Ovulation bleeding 0/17 (0%) 10/104 (10%) 
Miscarriage 2/13 (15%) 125/179 (70%) 
APH 3/11* (27%) 2/54* (4%) 
PPH 9/11 (82%) 7/54 (13%) 
* Viable pregnancies 
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3.3.1 Gynaecological bleeding: 
Menorrhagia (heavy menstrual bleeding, HMB) was  reported in 31/121 (26%) women in 
this literature review, making it the second most common bleeding symptom (Ikkala et al., 
1964; Girolami et al., 1977, 1986; Rodeghiero et al., 1987; Capellato et al., 1987; Boda et 
al., 1989; Burrows et al., 2000; Gmez-Garca et al., 2001; Lak et al., 2003; Peyvandi et al., 
2004; Bhattacharya et al., 2005; Lovejoy et al., 2006; Ivaskevicius et al., 2010b, 2007b, 
2010a; Singh et al., 2008). Umbilical bleeding was the commonest bleeding symptoms and 
reported in 33/121 (27%) women. 
 Severe ovulation bleeding as an intraperitoneal bleeding occurring at the time of ovulation 
was reported in 10/121 (8%) of women (Ikkala et al., 1964; Fisher et al., 1966; Meili, 2002; 
Lak et al., 2003; Melo, 2008; Singh et al., 2008; Chakravarty et al., 2012). In two women, it 
led to the diagnosis of FXIII deficiency (Ikkala et al., 1964; Meili, 2002).  Eight of these 
women were not on prophylaxis and two were on irregular prophylaxis using FFP. Six 
women required urgent surgical interventions including two women who had hysterectomy 
and bilateral salpingo-oophorectomy (Ikkala et al., 1964; Lak et al., 2003). Blood 
transfusion of 2-6 units was reported in four women (Fisher et al., 1966; Melo, 2008; Singh 
et al., 2008; Chakravarty et al., 2012). Prophylaxis to prevent further ovulation bleeding 
was started in four women. Details of women with ovarian bleeding are presented in Table 
3.2.  
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Table  3.4 Details of women with FXIII deficiency and ovulation bleeding 
Author 
(Year) 
FXIII activity Was on 
regular 
prophylaxis 
Clinical History Management Postoperative 
treatment and 
prophylaxis 
Chakravarty† 
et al, 2012 
Not specified Irregular 
use FFP 
Umbilical bleeding at 
birth, multiple bruises, 
ICH, pelvic and renal 
hematoma. Acute 
abdomen (ovarian 
haematoma) age 13 
years 
FFP (4 U) and 
Blood (3 U), 
Laproscopic  
blood clot 
removed (2 L) 
Blood (2U), 
tranexamic 
acid (500mg) 
for 2 days. 
OCP 
Singh et al, 
2008 
Not specified Irregular 
use FFP 
Umbilical bleeding at 
birth, multiple bruises, 
ICH, pelvic and renal 
hematoma. Oral and 
nasal bleeding. Acute 
abdomen (ovarian 
haematoma) age 13 
years 
FFP (4 U) and 
Blood (2 U), 
Laproscopic  
blood clot 
removed (2 L) 
Blood (4U), 
FFP (6 U),  
FFP /4-6 
weeks 
Meili, 2002 Berichrom test  
<5 IU/dL 
None Four episodes of 
corpus luteum rupture 
with abdominal 
bleeding,  
Laparotomy FXIII 
concentrate 
500 mg/month 
Fisher, 1966 Plasma soluble in 
5M urea and 1 % 
monochloroacetic 
acid. 
None Four hospital 
admission for pelvic 
haematoma. Nerve 
compression.  
Blood 
transfusion 
Not specified 
Ikkala, 1964 Plasma soluble in 
5 M urea and 1 % 
monochloroacetic 
acid. 
None Three consecutive 
severe intra-
abdominal bleeding at 
age 27 years. No 
previous bleeding 
history 
Blood (4 U). 
Hysterectomy 
and adenexial 
removal 
Not specified 
Melo, 2008 7.5 IU/dL None Recurrent haematurea. 
Rupture haemorrhagic 
ovarian cyst with 
haemoperitoneum 
(1.5L) 
Cryoprecipitate 
(8U) and RBC 
unit (2 U) 
cryoprecipitate 
6 U / month 
Lak et al, 
2003†† 
Not specified Not 
specified 
Not specified One had 
hysterectomy 
and salpingo-
oophorectomy 
 
† Both case report by Chakravarty et al and Singh et al share lots of similarities in their case description as if 
it is the same woman. However, no reference to that had been made in the papers.  †† case series including 
four women 
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3.3.2 Pregnancy outcome:  
Among women included in this literature review, pregnancy was reported in 63/121 (52%) 
women and a total of 192 pregnancies were observed: 127/192 (66%) resulted in a 
miscarriage and 65/192 (34%) reached viability stage.  A history of at least one miscarriage 
occurred in 42/63 (67%) women with history of pregnancy, while recurrent miscarriage, 
defined as three or more pregnancy loss, was reported in 16/63 (25%) women. The median 
number of miscarriages was five, (range1-13). Two miscarriages occurred between five and 
seven weeks of gestation (Cerenzia et al., 1999; Padmanabhan et al., 2004); 14  
miscarriages occurred between 8 and 12 weeks of gestation (Boda et al., 1989; Kobayashi 
et al., 1990; Padmanabhan et al., 2004; Dargaud et al., 2008); and 11 miscarriages between 
16 and 18 weeks of gestation (Boda et al., 1989; Gmez-Garca et al., 2001; Dargaud et al., 
2008). The gestational age in the remaining 100 miscarriages was not reported.   
Viability status (pregnancy progressed to 24 week of gestation or more) was reached in 65 
pregnancies and 62 delivered a live babies (Fisher et al., 1966; Girolami et al., 1977; 
Rodeghiero et al., 1987; Capellato et al., 1987; Boda et al., 1989; Kobayashi et al., 1990; 
Asahina et al., 1998; Burrows et al., 2000; Gmez-Garca et al., 2001; Meili, 2002; Lak et al., 
2003; Padmanabhan et al., 2004; Rott et al., 2004; Lovejoy et al., 2006; Takahashi et al., 
2007; Melo, 2008; Ivaskevicius et al., 2010a, 2010b; Naderi et al., 2012). There was one 
intrauterine death (IUD) at 37 week of gestation due to placental abruption (Cerenzia et al., 
1999), and two neonatal deaths after preterm delivery  at 25 (Dargaud et al., 2008), and 28 
weeks gestation (Gmez-Garca et al., 2001).   
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3.3.3 Bleeding complications during pregnancy:  
Among 65 pregnancies reaching viability, bleeding during early pregnancy was reported in 
only one woman; vaginal bleeding occurred in both of her pregnancies at 6 and 7 week 
gestations, and she was then started on prophylactic therapy with 500IU/week of FXIII 
concentrate until successful delivery at term (Kobayashi et al., 1990; Asahina et al., 1998).  
Antepartum haemorrhage (APH: bleeding after 24 weeks gestation) occurred in five 
pregnancies in four women. Two out of four women had FXIII-B deficiency (Girolami et 
al., 1977; Saito et al., 1990). Four out of five pregnancies with APH occurred while not 
prophylaxis therapy (Girolami et al., 1977; Saito et al., 1990; Abalovich et al., 2002).  One 
woman was on FXIII prophylactic therapy with APH at 32 week of gestation (Gmez-Garca 
et al., 2001). All five pregnancies resulted in healthy live babies. Three pregnancies were 
delivered through emergency caesarean section (Saito et al., 1990; Abalovich et al., 2002). 
3.3.4  Mode of delivery:  
The mode of delivery was reported in 23 pregnancies including 12 vaginal deliveries 
(Kobayashi et al., 1990; Asahina et al., 1998; Cerenzia et al., 1999; Burrows et al., 2000; 
Meili, 2002; Padmanabhan et al., 2004; Takahashi et al., 2007; Dargaud et al., 2008) and 11 
caesarean delivery (Fisher et al., 1966; Rodeghiero et al., 1987; Boda et al., 1989; Saito et 
al., 1990; Mikkola et al., 1997; Rott et al., 2004; Melo, 2008; Hanke et al., 2010; 
Ivaskevicius et al., 2010b). The indication for caesarean delivery was an emergency 
caesarean for APH in three pregnancies(Saito et al., 1990; Mikkola et al., 1997); cephalo-
pelvic disproportion in two (Rodeghiero et al., 1987; Saito et al., 1990); and  premature 
rupture of membrane in one (Rott et al., 2004). An elective caesarean delivery for breech 
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presentation was performed in two (Hanke et al., 2010; Ivaskevicius et al., 2010b) The 
indication for the caesarean delivery was not reported in the remaining three pregnancies 
(Fisher et al., 1966; Boda et al., 1989; Melo, 2008). 
3.3.5 Neonatal outcome:  
There were 62 live newborns; 61 delivered between 37 and 39 weeks gestation, one baby, 
delivered at 32 weeks (Gmez-Garca et al., 2001). Only eight babies had records of the cord 
blood FXIII level measuring 30, 31, 32, 43, 45, 58 and 107 IU/dL, respectively (Boda et al., 
1989; Kobayashi et al., 1990; Saito et al., 1990; Asahina et al., 2000; Gmez-Garca et al., 
2001). Newborn weight was available for eight babies: the weight at birth ranged from 
3000-3142gms in seven babies (Fisher et al., 1966; Rodeghiero et al., 1987; Boda et al., 
1989; Kobayashi et al., 1990; Asahina et al., 1998; Burrows et al., 2000), with one small for 
date weigh 2400 gm. There was one still birth at 37 week weighing 2400gm (23). There 
were also two neonatal deaths; one at 25 weeks and baby weighed 770 gm died few days 
later due to intracranial haemorrhage (Dargaud et al., 2008). The other neonatal death 
resulted from premature delivery at 28 weeks (Gmez-Garca et al., 2001).  
3.3.6 Postpartum haemorrhage (PPH):  
Primary PPH, was reported in 16/65 (25%) pregnancies that reached viability stage in 12 
women. Five women had FXIII-B deficiency (Girolami et al., 1977; Capellato et al., 1987; 
Saito et al., 1990; Burrows et al., 2000). Eight pregnancies had PPH while not on 
prophylaxis therapy (Girolami et al., 1977, 1986; Capellato et al., 1987; Saito et al., 1990). 
Treatment of PPH was only described in two cases; the first case required concentrated red 
cells, FFP and laparotomy for PPH (Saito et al., 1990), the second case required whole 
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blood transfusion (Girolami et al., 1977). Six women with PPH were reported as part of 
two case series, but no further details were available(Burrows et al., 2000; Ivaskevicius et 
al., 2010a). No detail about the estimated blood loss during delivery or information about 
secondary PPH was available. 
3.3.7 Prophylaxis during pregnancy:  
Prophylactic treatment was not given in 136 pregnancies. In 45 pregnancies, the mother 
received prophylactic replacement therapy. Information regarding the use of prophylactic 
therapy was not available in 11 pregnancies. Among the 136 pregnancies without 
prophylactic therapy, 124 (91%) resulted in miscarriage and only 12 progressed to viability 
stage (Girolami et al., 1977, 1986; Saito et al., 1990; Mikkola et al., 1997; Cerenzia et al., 
1999; Gmez-Garca et al., 2001). Bleeding following miscarriage occurred in two women 
without prophylactic therapy (Girolami et al., 1977; Dargaud et al., 2008); one woman 
developed disseminated intravascular coagulation following evacuation of retained product 
of conception and was treated with FFP, four units of red blood cells, and uterine artery 
embolisation (Dargaud et al., 2008).  
Twelve pregnancies reached viability stage without prophylaxis (Girolami et al., 1977, 
1986; Saito et al., 1990; Mikkola et al., 1997; Cerenzia et al., 1999; Gmez-Garca et al., 
2001) occurred in three women with FXIII-A deficiency with FXIII Activity less than 1, 3 
and 10 IU/dL respectively, and six woman with FXIII-B deficiency (FXIII activity 1, 3, 10, 
10, 10 and 24 IU/dL). Among these 12 pregnancies, APH occurred in three and PPH in 
eight pregnancies. Premature delivery at 28 weeks gestation resulting in neonatal death also 
occurred in one pregnancy without any bleeding complications (Gmez-Garca et al., 2001). 
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 Of the 45 pregnancies on prophylaxis, 40 (89%) delivered live babies (Fisher et al., 1966; 
Rodeghiero et al., 1987; Boda et al., 1989; Kobayashi et al., 1990; Asahina et al., 1998; 
Burrows et al., 2000; Gmez-Garca et al., 2001; Meili, 2002; Lak et al., 2003; Padmanabhan 
et al., 2004; Rott et al., 2004; Takahashi et al., 2007; Melo, 2008; Ivaskevicius et al., 
2010b; Naderi et al., 2012), one IUD at 37 week of gestation due to placental abruption 
(Cerenzia et al., 1999); one neonatal death due to intracranial haemorrhage following 
preterm delivery after premature rupture of membrane at 25th week (Dargaud et al., 2008); 
and three (7%) resulted in a miscarriage at 7,9 and 11 weeks gestation (Cerenzia et al., 
1999; Asahina et al., 2000; Padmanabhan et al., 2004). Data on the use of prophylactic 
therapy was not available in nine pregnancies, all resulting in live births (Burrows et al., 
2000; Hanke et al., 2010).  
FXIII concentrate was the most common prophylactic treatment used in 33 pregnancies 
(Rodeghiero et al., 1987; Kobayashi et al., 1990; Asahina et al., 1998, 2000; Cerenzia et al., 
1999; Burrows et al., 2000; Gmez-Garca et al., 2001; Meili, 2002; Rott et al., 2004; 
Takahashi et al., 2007; Dargaud et al., 2008; Ivaskevicius et al., 2010b; Naderi et al., 2012); 
the dose varied between 500 U every one to four weeks in four pregnancies (Rodeghiero et 
al., 1987; Kobayashi et al., 1990; Asahina et al., 1998; Burrows et al., 2000). The dose was 
increased in two pregnancies from 500 U to 750 U every two weeks at the 22nd week of 
gestation (Meili, 2002), and to 1250 U per week at 32 weeks of gestation(Takahashi et al., 
2007).  A dose of 10 U /kg was given every four weeks before pregnancy and then every 
two weeks during pregnancy in 17 pregnancies (Naderi et al., 2012). One woman with 
FXIII-B deficiency received 2500 U prior to caesarean delivery (Ivaskevicius et al., 2010b).  
86 
 
Cryoprecipitate was used in five pregnancies in a dose of 1-2 U every two 
weeks(Padmanabhan et al., 2004) and in a dose of 6-8 U per month (Lak et al., 2003; 
Padmanabhan et al., 2004). Human blood banked plasma was used in two pregnancies in 
dose of 300-400 ml every 10 days (Fisher et al., 1966; Boda et al., 1989) and FFP was used 
in two pregnancies in a dose of 300-450 ml every two weeks (Rodeghiero et al., 1987; 
Boda et al., 1989). Plasma FXIII level was kept in a range of 3-70 IU/dL with a median of 
12 IU/dL during pregnancy. During labour and delivery, FXIII level was maintained at a 
median of 35 IU/dL ( range 19-62 IU/dL) (Boda et al., 1989; Kobayashi et al., 1990; 
Asahina et al., 1998, 2000; Burrows et al., 2000; Rott et al., 2004; Takahashi et al., 2007; 
Hanke et al., 2010).  
Two women received FXIII replacement therapy for primary infertility management: one 
woman with a two year history of primary infertility became pregnant two months after 
receiving 300-450 ml FFP every two weeks, and had a further pregnancy while on 500U 
FXIII concentrate every three weeks (Rodeghiero et al., 1987); the second woman had a 
FXIII activity of 50 IU/dL and a history of primary infertility with five unsuccessful 
attempts of IVF- this woman was treated with 2500 U FXIII every 10 days prior to and 
during her 6th IVF attempt and a successful pregnancy resulted in a live baby (Rott et al., 
2004).  
3.4  Discussion: 
Heavy menstrual bleeding is a common bleeding symptom in women with inherited 
bleeding disorders. In two previous case series,  heavy menstrual bleeding was reported in 
35% (Lak et al., 2003) and  64% (Burrows et al., 2000) women with congenital FXIII 
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deficiency. In this review, menorrhagia was reported in 28% of women. However, this is 
most likely to be an underestimate as most case reports did not provide information on 
menstrual bleeding. In addition, due to the genetic nature of this condition, many women 
from the same family can be affected and have heavy menstrual bleeding. Such heavy 
periods may be viewed by women in these families as normal therefore leading to under 
reporting of menstrual problems. 
Women with FXIII deficiency appear to be at an increase risk of significant ovulation 
bleeding leading to acute abdomen requiring surgical intervention, pelvic haematoma or 
haemorrhagic ovarian cysts (Inbal and Kenet, 2003). In a case series of 20 women with 
FXIII deficiency, 20% had a history of ovulatory bleeding (Lak et al., 2003). In this 
systematic review, severe ovulation bleeding leading to haemo-peritoneum occurred in 8% 
of the women. Management of such ovarian bleeding in the presence of FXIII deficiency 
poses additional challenges. There is a risk of further bleeding during surgery, which may 
require oophorectomy to control the bleeding, thus compromising the patient future 
fertility.  Prevention of such bleeding by suppression of ovulation, and a conservative 
approach when the bleeding occurs, are the best option, as repeated haemorrhagic cysts and 
surgical removal of these cysts can cause ovarian damage (Ho et al., 2002; Ragni et al., 
2005; Duru et al., 2007). 
Women with FXIII deficiency have a significant risk of recurrent pregnancy loss.  In this 
systematic review, 66% of the pregnancies resulted in a miscarriage. Animal studies have 
shown that mice with homozygous FXIII deficiency are more vulnerable to develop 
intrauterine bleeding and miscarriages. In a study of mice with homozygous FXIII-A 
deficiency, the histological examination of the uterine tissue showed blood pooling in the 
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uterine cavity adjacent to the placenta and not in the amniotic cavity or the fetus. On the 
other hand, an intact placenta or uterus, was shown to be associated with a normal 
development of fetus even in homozygous mice.  These findings suggest a maternal source 
of haemorrhage due to vascular breakage in the placenta, and that FXIII is crucial for the 
prevention of intrauterine bleeding and maintenance of pregnancy (Koseki-Kuno et al., 
2003). 
Although there is a significant increase in the risk of miscarriage (Kobayashi et al., 1990; 
Asahina et al., 1998), not all pregnancies in women with congenital FXIII deficiency result 
in a pregnancy loss. In this systematic review, 12 pregnancies in nine women progressed to 
viability stage and 11 delivered a live baby at term without receiving any replacement 
therapy prior or during pregnancy. However, three of the pregnancies were associated with 
APH (Girolami et al., 1977; Saito et al., 1990; Mikkola et al., 1997) and one had preterm 
delivery lead to a neonatal death (Gmez-Garca et al., 2001). There was also PPH in eight 
pregnancies (Girolami et al., 1977, 1986; Capellato et al., 1987; Saito et al., 1990). It was 
noted that six of these nine women, not on prophylaxis, were cases with FXIII-B 
deficiency.  Clinical features of cases suffering from congenital FXIII-B deficiency are 
usually of milder course with less risk of severe bleeding compared to those with FXIII-A 
deficiency (Ichinose, 2001, 2012). Women with FXIII-B deficiency are able to conceive 
and progress to deliver live babies, despite the lack of replacement therapy (Ichinose, 
2012). This may be explained by the presence of some residual FXIII activity.  However, 
almost all of these women developed APH or PPH as well as post surgical bleeding. This 
was highlighted in this systematic review as the miscarriage rate (15%) was not higher than 
what is reported in the general population. However there was a higher frequency of both 
APH (27%) and PPH (82%) among these women.  
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This suggests that while FXIII activity in women with FXIII-B deficiency, reduces the 
chance of early pregnancy loss and spontaneous bleeding, is not enough to prevent bleeding 
complications during haemostatic challenges. 
Three pregnancies resulted in a miscarriage despite being on prophylactic therapy during 
pregnancy. In these cases, low dose of treatment and/or missing prophylaxis have been 
reported as a possible cause for this adverse pregnancy outcome (Cerenzia et al., 1999; 
Asahina et al., 2000; Padmanabhan et al., 2004). 
The exact prevalence of PPH among women with congenital FXIII deficiency is unclear. 
PPH is believed to occur less frequently in FXIII deficiency compared to other bleeding 
disorders (Peyvandi et al., 2011b), possibly because most women during pregnancy and 
delivery are receiving prophylactic therapy.  FXIII concentrate has a long half life of 10-14 
days. Thus, its protective effect extends to the postpartum period. In this systematic review, 
25% of the deliveries were complicated with PPH; this is much higher than the prevalence 
of 8-10% reported in the general population (Carroli et al., 2008).  
The finding of this review confirms that successful pregnancies in women with FXIII 
deficiency are generally only achieved with replacement therapy throughout pregnancy.  
However, it is not clear what level of FXIII is required for a successful pregnancy and safe 
delivery. Maintaining a FXIII level higher than 10-20 IU/dL has been recommended by 
some authorities (Peyvandi et al., 2011a). The United Kingdom Haemophilia Centre 
Doctors’ Organisation(UKHCDO) recommends haemostatic cover with FXIII concentrate 
given monthly to all girls from the time of diagnosis and continued throughout pregnancy, 
aiming to keep the FXIII level >3 IU/dL (Bolton Maggs et al., 2004). In this systematic 
review, among 41 pregnant women on prophylaxis treatment reaching viability stage, the 
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plasma FXIII level was maintained at a median of 12 IU/dL (range 3 to70 IU/dL) during 
pregnancy, and a median of 35 IU/dL (range 19-62 IU/dL) during labour and delivery.  
FXIII concentrate is the recommended treatment option and was the most common type of 
prophylactic therapy used during pregnancy and labour. Other treatment options include 
FFP and cryoprecipitate. There is no consensus on the optimal dose of FXIII concentrate 
but a dose of 250 IU weekly early in pregnancy until 23rd week, increased thereafter to 500 
IU per week is recommended and widely used. For labour and delivery, a booster dose of 
1000 IU is recommended to prevent PPH (Asahina et al., 2007; Peyvandi et al., 2011a).  
Newborns of mothers with FXIII deficiency are at risk of being born preterm as a 
consequence to placental abruption. In a recent study among women with normal 
coagulation, perinatal mortality in  pregnancies complicated with placental abruption was 
102 compared to 6 per 1,000 births in  those without abruption, mainly due to preterm 
delivery that occurred in 28% of cases (Ananth and VanderWeele, 2011). 
FXIII replacement therapy during pregnancy can reduce the risk of placental abruption in 
women with FXIII deficiency. Therefore, these mothers should be managed in 
collaboration with a haemophilia centre with facilities to provide the haemostatic cover and 
regular monitoring of factor levels. In addition, obstetric management should include 
identification of any additional risk factor for preterm labour with regular surveillance and 
implementation of appropriate measure to improve outcome.  Pregnancy should be 
managed in a unit with tertiary neonatal facilities with a facility to care for preterm babies. 
 FXIII deficiency is an autosomal recessive disorder. Thus, the baby has a 50% chance of 
being heterozygous for FXIII deficiency. Individuals with heterozygous FXIII deficiency 
have a residual FXIII activity around 30–60% and are usually asymptomatic with no 
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spontaneous bleeding. However, delayed bleeding may develop under special conditions 
such as post surgery or dental extraction or following physical trauma. Therefore, 
heterozygote neonates are potentially at risk of bleeding during the process of labour and 
delivery, mainly head bleeding seen in traumatic delivery. In communities with 
consanguineous marriage, the neonate may be affected (homozygote) with FXIII deficiency 
with significant risk of bleeding, the commonest being umbilical bleeding (Anwar and 
Miloszewski, 1999; Anwar et al., 2002; Karimi, 2009); thus, partner screening should be 
considered in such communities. No specific study was found on the prevalence of 
intracranial haemorrhage among neonates with FXIII deficiency and there are no data or 
recommendations on the mode of delivery (Bolton Maggs et al., 2004). intracranial 
haemorrhage is more common among neonates with a history of prolonged labour and 
delivery using forceps or vacuum extraction, while caesarean delivery carries the lowest 
risk of intracranial haemorrhage in neonates in general and those affected with severe 
bleeding disorders such as haemophilia (Rooks et al., 2008). Therefore each case should be 
assessed individually by a multidisciplinary group including the mother, and prolonged, 
difficult deliveries should be avoided with early referral for caesarean delivery to minimise 
the risk. A planned caesarean delivery is increasingly used for delivery of babies affected 
with inherited bleeding disorders (Chi and Kadir, 2012) and should be considered if there is 
any additional risk for intracranial haemorrhage or if the labour is expected to be prolonged 
or difficult.   
FXIII plays an important role in implantation that includes a complex interface between 
uterus and blastocyst through the action of activated FXIII on cross linking fibrin, 
fibrinogen and fibronectin which is essential in placental attachment to uterine tissue. 
FXIII-A has been detected within the extracellular spaces of extravillous cytotrophoblasts, 
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as well as the Nitabuch’s layer adjacent to the cytotrophoblastic shell (Kobayashi et al., 
1999). It is believed that women with FXIII deficiency lack FXIII in placental bed resulting 
in failure of implantation and very early pregnancy loss due to poor formation of the 
cytotrophoblastic shell (Asahina et al., 1998, 2000, 2007). In this systematic review, two 
women with primary infertility, and repeated IVF failure, were able to have three 
pregnancies following administration of FXIII replacement therapy. The role of FXIII in 
the process of implantation and early pregnancy development is not well studied.  Studies 
are required to assess the role of systematic and local (placental bed) level of FXIII in the 
process of implantation, and whether replacement and normalisation of FXIII can improve 
outcome in patient with implantation failure and early pregnancy losses.  
In conclusion, this systematic review indicates that women with congenital FXIII 
deficiency suffer significant bleeding complications. However, we acknowledge the 
unavoidable limitation of this review as the clinical data varied markedly in content and 
quality between the reports and that reporting bias may have favoured descriptions of 
adverse gynaecological and obstetric events.  
Menorrhagia and ovulation bleeding are common gynaecological problems and possibly 
more prevalent than reported. Pregnancies in women with FXIII deficiency have a 
significant risk of miscarriage, placental abruption, preterm delivery and PPH if not treated. 
Therefore, replacement therapy is essential to achieve successful pregnancy and to reduce 
the risk of bleeding during pregnancy, preterm delivery and PPH. The treatment of choice 
is FXIII concentrate, aiming to keep FXIII level between 3-10 IU/dL. In pregnancy, the 
dose is measured to keep FXIII level of > 10 IU/dL. For delivery, a booster dose may be 
necessary, especially if the delivery is operative to prevent PPH. Increased awareness 
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among clinicians and a multidisciplinary approach is essential when managing the 
gynaecological and obstetrical issues affecting women with FXIII deficiency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
 
 
CHAPTER FOUR 
 
FXIII LEVELS AND ITS CHANGES IN PREGNANCY AND 
IMMEDIATE POSTPARTUM PERIOD 
  
 
 
 
 
 
 
95 
 
4 CHAPTER FOUR:  FXIII LEVELS DURING PREGNANCY AND 
IMMEDIATE POSTPARTUM PERIOD  
4.1 Introduction: 
Factor XIII (FXIII), fibrin stabilising factor, circulates in plasma as a heterodimer 
composed of two catalytic A-subunits and two carrier B-subunits (Muszbek et al., 1996).  
The A-subunits are produced by the haematopoietic cells (megakaryocyte and 
monocyte/macrophage) in the bone marrow whereas the B-subunits are produced in the 
liver (Wölpl et al., 1987). The main function of FXIII is in haemostasis, wound healing and 
the maintenance of pregnancy (Board et al., 1993; Anwar and Miloszewski, 1999). 
Variations in FXIII level can be attributed to many physiological and pathological factors. 
Significantly higher levels of the FXIII A subunit have been found among women and 
smokers, and there was an effect of age (Ariëns et al., 1999). The same study found FXIII 
B-subunit antigen and FXIII activity levels to be significantly correlated with the level of 
fibrinogen (Ariëns et al., 1999). The FXIII level has also shown to be increased in non–
insulin-dependent diabetic patients with micro-angiopathy (Kłoczko et al., 1986).  
Normal pregnancy is associated with significant changes in coagulation parameters 
(Franchini, 2006). A recent study found a marked increase in fibrinogen level and 
coagulation factors VII, VIII, and IX during pregnancy, delivery and postpartum; factors II, 
V, X, XI, XII, protein C and antithrombin, remained largely unchanged; while protein S 
activity decreased substantially (Szecsi et al., 2010). Changes in FXIII level during 
pregnancy have been assessed in very few studies and these contained small numbers of 
samples. These studies show a decrease in FXIII during the third trimester, however the 
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minimum level required for fetal implantation and maintaining haemostasis during 
pregnancy are unknown. Furthermore the reference range of FXIII in pregnant women 
during the three trimesters of pregnancy has yet to be established (Rodeghiero et al., 1987; 
Boda et al., 1989; Burrows et al., 2000; Asahina et al., 2007).  
The aim of this study was to establish the reference ranges for FXIII level during pregnancy 
and immediate puerperium and to assess changes in the level of FXIII during the three 
trimesters of a normal uncomplicated pregnancy. The relationship between the level of 
FXIII during pregnancy and the demographics of the women was also investigated. 
4.2 Materials and Methods: 
4.2.1 Study design:  
This is a cross sectional study of 376 pregnant women, who attended the antenatal clinic at 
the Royal Free Hospital in London from October 2011 to July 2012. The study was 
approved by the hospital ethics committee and informed consent was obtained from 
participating women. Only women with a normal, uncomplicated pregnancy were included 
in the study.  Women on anticoagulant or non-steroidal anti-inflammatory therapy and with 
personal or family history of bleeding disorders, or with any obstetric complications such 
as pre eclampsia and intrauterine growth retardation were excluded from the study. 
Demographic data were obtained by direct interview with the women and from the obstetric 
case notes. These data included:  age; maternal weight at the time of the blood sample, 
smoking status, previous obstetric history (number of pregnancies; previous miscarriages, 
history of gestational hypertension and history of previous intra-uterine growth retardation) 
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and gestational age at the time of taking the blood sample. The obstetric notes were also 
reviewed after delivery for any obstetric complications subsequent to the blood sample, sex 
of the newborn, birth weight and gestational age and estimated blood loss (EBL) at 
delivery. Primary postpartum haemorrhage (PPH) was defined as blood loss in the first 
24 hour after delivery with an estimated blood loss of  more than 500 ml for normal vaginal 
deliveries, or more than 1000 ml for caesarean sections (RCOG, 2009). 
The pregnancy duration was calculated based on the 1st trimester ultrasound determination. 
This is performed routinely for all pregnant women between11-13+6 weeks of gestation and 
gestational age is defined based on the crown-rump length. For the purpose of this analysis, 
pregnant women are divided into three groups based on their gestational age; first trimester 
group (gestational age 0-12 weeks, n=116), second trimester group (gestational age 13-28 
weeks, n=132), third trimester group (gestational age 29-42 weeks, n=128) and immediate 
puerperium or postnatal (0-3 days post-delivery, n=30).  
Sample numbers were chosen based on the International Federation of Clinical Chemistry 
(IFCC) recommendation to use a minimum sample size of 120 for calculating reference 
values (Horowitz et al., 2008). Blood samples were also collected from 25, age matched, 
healthy non-pregnant women as a control group. 
In addition, a longitudinal study of 26 pregnant women was performed from the same study 
population who were followed up throughout pregnancy to measure FXIII activity during 
1st, 2nd, and 3rd trimester of pregnancy.  
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4.2.2 Laboratory Methods:   
After obtaining written informed consent, blood samples were obtained between 11:00 a.m. 
and 2:00 p.m. after a resting period of 10 minutes. Venous blood samples were collected by 
clean venepuncture, with minimal stasis, into citrate (0.105 mol/L) VacutainersTM (BD 
Diagnostics, Oxford, UK), with a ratio of one part anticoagulant to 9 parts whole blood. 
Within one hour of collection platelet poor plasma (PPP) was prepared by double 
centrifugation at ambient temperature (2000g for 10 minutes) and aliquots of PPP were 
frozen to -80ºC. On the day of assay samples were thawed to 37ºC. 
Factor XIII activity was determined  using a chromogenic ammonia release assay 
(Berichrom® FXIII assay; Siemens Healthcare Diagnostics, Marburg, Germany) performed 
on a CS-5100 coagulation analyser (Sysmex UK Ltd, Milton Keynes) as described by 
Lawrie et al (Lawrie et al., 2010). FXIII potencies were calculated relative to Standard 
Human Plasma (SHP, Siemens Healthcare Diagnostics). The manufacturer’s stated normal 
reference range was 70-140 IU/dL (Figure 4.1).  
4.2.3 Statistical Analysis:  
Descriptive statistics were performed for the demographic data and continuous data were 
presented as mean and standard deviation (SD). Variation in the mean FXIII levels between 
variable studied groups was assessed using unpaired student t-test. The longitudinal study 
on FXIII level changes during pregnancy was studied using paired student t-test. Data were 
analysed using SPSS statistical package, version 20.0 (SPSS Inc., Chicago, IL, USA). 
Level of significance was set at p ≤ 0.05. 
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Figure  4.1 Example of a Berichrom® F XIII assay Standard curve 
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4.3 Results: 
The demographic information of the women is presented in Table 4.1. The median age was 
31 years (range 19 to 46 years). Only seven (2%) of the women were smokers. There were 
116 women in the 1st trimester, 132 women in the 2nd trimester, 128 women in the 3rd 
trimester of pregnancy, and 30 women in the postnatal period.   
FXIII activity was normally distributed throughout the gestational age and within each of 
the gestational age range groups (Figure 4.2, Figure  4.3, Figure 4.4). The mean ± SD FXIII 
activity was 112 ±29 IU/dL during the first trimester, 96 ± 26 IU/dL during the second 
trimester, 83± 21 IU/dL during the third trimester, 90 ± 19 IU/dL during postnatal period, 
and 113± 26 IU/dL among control group. FXIII range (Mean ± 2 SD) for the first trimester 
was 55 to 169 IU/dL (six results less than 70 IU/dL), for the second trimester 45 to 147 
IU/dL (15 results less than 70 IU/dL), for the third trimester 42 to 125 IU/dL (34 results 
less than 70 IU/dL), for postnatal period 61 to 137 IU/dL (Five results less than 70 IU/dL) 
and for control group 61 to 165 IU/dL ( no results were below 70 IU/dL) as seen in Table 
4.2, Figure  4.5 Figure  4.6 and Figure  4.7.  
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Table  4.1. The distribution of women age, weight, gravid, gestational age and smoking 
status among all three trimesters of pregnancy 
 1ST Trimester 2NDTrimester 3RDTrimester TOTAL 
Women  
included 
n = 116 n = 132  n = 128  n = 376  
Gravida     
Unknown 19 (16.4) 7 (5.3) 14 (10.9) 40 (10.6) 
1 29 (25.0) 50 (37.9) 36 (28.1) 115 (30.6) 
2 38 (32.8) 38 (28.8) 40 (31.3) 116 (30.9) 
3 14 (12.1) 16 (12.1) 19 (14.8) 49 (13.0) 
4+ 16 (13.8) 21 (15.9) 19 (14.8) 56 (14.9) 
Miscarriages     
Unknown 19 (16.4) 7 (5.3) 14 (10.9) 40 (10.6) 
0 73  (62.9) 90 (68.2) 81 (63.3) 244 (64.9) 
1 14 (12.1) 23 (17.4) 27 (21.1) 64 (17.0) 
2 6 (5.2) 8 (6.1) 3 (2.3) 17 (4.5) 
3+ 4 (3.4) 4 (3.0) 3 (2.3) 11 (2.9) 
Para     
Unknown 19 (16.4) 7 (5.3) 14 (10.9) 40 (10.6) 
0 41 (35.3) 66 (50.0) 53 (41.4) 160 (42.6) 
1 36 (31.0) 37 (28.0) 39 (30.5) 112 (29.8) 
2 16 (13.8) 15 (11.4) 9 (9.0) 40 (10.6) 
3+ 4 (3.4) 7 (5.3) 13 (10.2) 24 (6.4) 
Smoker     
Unknown  6 (5.2) 5 (3.8) 6 (4.7) 17 (4.5) 
No 108 (93.1) 123 (93.2) 121 (94.5) 352 (93.6) 
Yes 2 (1.7) 4 (3.0) 1 (0.8) 7 (1.9) 
Gestation 
(wks); Median 
(range) 
10 (7, 14) 25 (13, 29) 34 (13, 39) 26 (7, 39) 
Age (years); 
Median (range) 
31 (19, 42) 
n=103 
31 (19, 46) 31 (20, 46) 
n=126 
31 (19, 46) 
n=361 
Body weight 
(kg); Median 
(range) 
63.5 (43, 122) 
n=82 
68.5 (43, 180) 
n=78 
74 (50, 119) 
n=93 
70 (43, 180) 
n=253 
Unless otherwise stated the numbers given in parenthesis indicate the percentage of that group 
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Figure  4.2 The distribution of FXIII activity (IU/dL) during first trimester of 
pregnancy 
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Figure  4.3 Distribution of factor XIII activity (IU/dL) in the second trimester 
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Figure  4.4 Distribution of Factor XIII activity (IU/dL) in the third trimester 
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Figure  4.5 Plot and Linear regression of FXIII activity (IU/dL) in relation to the week of 
gestation. 
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Figure  4.6 Factor XIII activity distribution among control, 1st, 2nd and 3rd trimester 
of pregnancy, and postnatal period. Central transverse line representing mean factor 
XIII activity while the upper and lower lines represent the standard deviation of the 
mean. 
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Figure  4.7 Mean and standard error of the mean for FXIII activity among control 
group and during each trimester of pregnancy and postnatal period.  
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Table  4.2 Reference intervals of FXIII activity (IU/dL) during each trimester of 
pregnancy and postnatal period 
Reference range 
(centile) 
FXIII 
activity 1st 
trimester 
FXIII activity 
2ndtrimester 
FXIII activity 
3rdtrimester 
FXIII activity 
Postnatal 
2.5% 55 45 42 61 
3% 57 47 44 62 
5% 64 53 49 62 
10% 74 63 56 64 
25% 92 78 69 77 
50% (mean) 112 96 83 90 
75% 131 114 98 100 
90% 149 130 110 123 
95% 160 139 118 131 
97% 166 145 123 135 
97.5% 169 147 125 137 
Standard 
Deviation 
29 26 21 19 
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The difference in the mean FXIII activity between each trimester of pregnancy was 
statistically significant with FXIII activity being lower during second and third trimester 
compared to the first trimester (p<0.0001). FXIII activity was also lower in third trimester 
compared to second trimester of pregnancy (p<0.0001). Furthermore, the mean FXIII 
activity during the second and third trimester of pregnancy was significantly lower 
compared to the non-pregnant control group (96 versus 115 IU/dL, p = 0.001; and 84 
versus 115 IU/dL, p <0.0001, respectively), however, there was no significant difference 
between FXIII activities during first trimester compared to the control group (112 versus 
115 IU/dL, p = 0.64).  
The mean FXIII activity during postnatal period was significantly lower compared to the 
first (p< 0.0001) trimester of pregnancy but not with the second (p= 0.2) and third (p = 
0.12) trimester of pregnancy. The mean postnatal FXIII activity was significantly lower 
when compared to control group (90 versus 115 IU/dL, p=0.0002).  
There was a weak, positive correlation (r=0.16, p=0.02) between FXIII activity and age. 
FXIII activity was measured in a fresh sample, six weeks postnatally, in a cohort of ten 
women recruited out of 55 women with low FXIII levels in their second and third trimester 
of their pregnancy. In all cases, the postnatal FXIII levels had returned to the normal range. 
Review of medical records for pregnancy outcome and other clinical data was available in 
333 cases. Antepartum haemorrhage (APH) was noted in eight (2 %) of the pregnancies, all 
of these women had FXIII activity above 70 IU/dL, with one exception, who had a FXIII 
activity of 67 IU/dL in a sample taken during first trimester of pregnancy.  The median 
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estimated amount of blood loss post-delivery was 400 ml (range 30 to 4000 ml).  
Postpartum haemorrhage (PPH) was seen in 65/333 (20%) of women.   Using Spearman’s 
correlation coefficient, there was no significant relationship between FXIII activity during 
pregnancy and estimated blood loss post-delivery (rs= 0.56, p= 0.30).  
The mean birth weight of the newborn was 3.34 kg. There were 12 (4%) infants delivered 
prior to 37 week of gestation, and 8 (2.4%) with low birth weight (weight <2.5 kg and born 
≥ 37 weeks of gestation). There was no significant difference in FXIII activity during 
pregnancy in 20 women who had a low birth weight newborn (median 92, range 64-137 
IU/dL) compared with those with a normal birth weight (median 91, range 27-170 IU/dL) 
using Mann-Whitney test (p=0.70). Similarly, there was no significant difference in FXIII 
activity between 20 women who delivered preterm (before 37 weeks of gestation) and 313 
women delivered term babies (>37 weeks) (p=0.10). 
Analysis of samples from 26 women with FXIII activity measured sequentially during at 
least two trimesters of their pregnancy is presented in Table 4.3. The mean FXIII activity 
during second and third trimester of pregnancy was lower compared to the first trimester, 
but the difference did not reach statistical significance and not all women had the FXIII 
activity measured through all three trimesters of pregnancy. 
 
 
 
 
111 
 
 
Table  4.3  Change in FXIII activity among 26 women throughout a minimum two 
trimesters of pregnancy. 
Time point being considered  Difference in FXIII between time 
points 
p-value* 
1 2 N Mean difference SD  
1ST trimester 2ND trimester 10 -16 26 0.0836 
1ST trimester 3RD trimester 8 -12 18 0.0947 
2NDtrimester 3RDtrimester 16 -8 26 0.2340 
Paired t-test; results also consistent when using non-parametric equivalent 
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4.4 Discussion 
Reference ranges for coagulation factors during pregnancy, delivery and the immediate 
postpartum period have recently been established in a study including 186 women with 
uncomplicated pregnancies (Szecsi et al., 2010); but the FXIII was not included. This large 
study establishes the reference range for FXIII during the three trimesters of pregnancy and 
the immediate postpartum period. It confirms previous findings that FXIII significantly 
reduces with advancing gestation with a significant reduction in the third trimester 
compared to the first and second trimesters of pregnancy (Nossel et al., 1966; Coopland et 
al., 1969; Biland and Duckert, 1973; Hayano et al., 1982; Wersch et al., 1997). 
In a previous study (Wersch et al., 1997), changes in FXIII level during pregnancy were 
assessed among 75 non-smoking pregnant women compared to 118 smoking pregnant 
women and a control group of pill-using non-smoking women. All women were ranked 
into four groups based on the gestational age (0-10 weeks, 11-20 weeks, 21-30 weeks, and 
31-40 weeks) and FXIII level was significantly lower at 31- 40 week of pregnancy 
compared to 0-10 weeks of pregnancy, regardless of smoking status. This decline in FXIII 
level with advancing gestation is in agreement with our findings (Wersch et al., 1997). 
Smoking has also been shown to affect the decline in FXIII level during pregnancy. FXIII 
levels during the first trimester were significantly higher in smokers compared to the 
control group, but it was not significant in the non-smokers. In addition, a decline of XIII 
level started from 20 weeks of gestation for non-smoking women, but from 30 weeks of 
gestation for smokers (Wersch et al., 1997), and smokers had a significantly higher level of 
FXIII compared to non-smokers during the second half of pregnancy. It has been 
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speculated that the rise of FXIII is due to relative polycythaemia and platelet activation. In 
our study there were only seven smokers, an insufficient number to establish any possible 
correlation with smoking.  
In a further study of 39 pregnant women and a control group of 10 non-pregnant women, a 
steady decline in plasma FXIII concentration was reported with advancing gestation. The 
study showed no significant difference between the samples taken 12-20 weeks of gestation 
compared to the control group. However, the mean FXIII level was significantly lower 
during 20-30 weeks of pregnancy and 30 weeks to term compared to the control group. The 
method of analysing FXIII was the clot solubility assay; this incorporates 125Iodine-labelled 
fibrinogen, to provide a quantitative endpoint by measuring the radioactivity of clot 
supernatant (Coopland et al., 1969). 
In our study, ten of the women with FXIII activity <70 IU/dL were found to have normal 
FXIII levels when they were retested during the immediate postpartum period. It is not 
clear whether the reduction of plasma FXIII during pregnancy represents reduced synthesis 
of FXIII-A, increased consumption, or is due to haemodilution. In normal pregnancy, there 
is an average 50% increase in maternal blood plasma volume, beginning around the 10th 
week of gestation up to the 34-36th week of gestation (Hytten, 1985).  However, other 
coagulation factors such as factor VII, VIII, and IX tend to increase during pregnancy 
despite hemodilution (Bremme, 2003), possibly due to an increase in the synthesis of these 
factors. In a study of coagulation factors among newborn and their mothers, the FXIII 
activity in 50 women was measured shortly before delivery and found to be lower than the 
FXIII level in the cord blood of their babies.  The authors speculated on a possible passage 
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of FXIII to the fetal circulation to explain the reduction in maternal plasma FXIII level near 
delivery (Biland and Duckert, 1973).  
Another study compared FXIII changes in the third trimester of normal pregnancy and 
pregnancies complicated by intrauterine growth retardation (IUGR). FXIII level was 
maintained in the IUGR group, while in the normal pregnancy, there was a significant 
reduction compared to mid-pregnancy (Persson et al., 1980). This suggests that the 
reduction in FXIII level seen during the third trimester of pregnancy is related to maternal 
FXIII transfusion through the placenta to the fetus. Those with IUGR fail to consume 
maternal FXIII possibly due to reduced placental transfusion to the fetus, thus maintaining 
higher plasma FXIII during the third trimester of pregnancy. A further possible explanation 
is that placental growth and expansion requires an increasing consumption of maternal 
FXIII due to its role in trophoblastic invasion, resulting in a progressive reduction of 
plasma FXIII level toward the end of pregnancy. IUGR is associated with poor growth and 
development of the placenta and thus fails to consume maternal FXIII. 
In conclusion, our study demonstrates a progressive decline in FXIII levels during the three 
trimesters of pregnancy and provides the reference range for FXIII level during pregnancy. 
It also shows a reduced FXIII levels in the immediate postnatal period. Knowledge of the 
FXIII reference range is helpful for appropriate management of FXIII deficiency in 
pregnancy. It can also improve our understanding of the role of FXIII in pregnancy related 
complications. Further studies are required to assess the role of FXIII level and its changes 
in pregnancy complicated by placental insufficiency and IUGR. 
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5 CHAPTER FIVE:   PLASMA FXIII LEVEL VARIATIONS 
DURING MENSTRUAL CYCLE 
5.1 Introduction 
Many physiological variables affect coagulation factor levels, including age, sex, race, 
blood group and female sex hormones. Cyclical variations of the female sex hormones have  
been reported during the menstrual cycle (Kadir et al., 1999a; Knol et al., 2012).  
During the menstrual phase of the cycle, FXIII could be important in the process of healing 
the endometrium and controlling the menstrual blood loss through fibrin cross-linking, thus 
improving the mechanical strength, rigidity and elasticity of the clot and prevent it from 
being dissolved through fibrinolysis (Muszbek et al., 1996).  However, the effect of the 
menstrual cycle on FXIII levels is not been fully understood and it is also not clear whether 
endometrial healing leads to an increase in FXIII consumption, thus altering the plasma 
level. Variations in FXIII level during the menstrual cycle, if present, would need to be 
considered when performing screening tests for FXIII deficiency. The aim of this study was 
to examine possible changes in plasma FXIII activity during the normal menstrual cycle 
and to assess any correlation between FXIII activity during the menstrual phase and the 
menstrual blood loss.  
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5.2 Materials and Methods 
5.2.1 Study design: 
This was a longitudinal study of 32 women of reproductive age. Women were recruited 
from hospital staff through leaflet and poster invitations at Royal Free Hospital NHS 
Foundation Trust, from January to October 2012. Women were included in the study if they 
had a regular menstrual cycle of 26-35 days duration, and were not using hormonal 
contraception, including Mirena® IUS (levonorgestrel-releasing intrauterine system), and 
were not using non-steroidal anti-inflammatory drugs. Exclusion criteria also included 
personal or family history of bleeding tendency or thrombo-embolism. The study was 
approved by the hospital ethical committee and informed consent was obtained from 
participating women.  
Demographic and clinical data collected include: age, ethnicity, previous number of 
pregnancies and miscarriages, body mass index (BMI), and smoking status through an 
interview with the women. 
Menstrual blood loss was measured using the pictorial blood-assessment chart (PBAC) 
(Higham et al., 1990). The women were given oral and written instructions on the use of 
PBAC and were asked to complete the chart during the period of blood sample collection. 
Women were required to document the number of sanitary pads and/or tampons used each 
day (24 hour) based on the degree of saturation of the pads/tampons, they were also asked 
to record the number and size of blood clots if present (Appendix 4).  The completed PBAC 
sheets were collected at the end of the menstrual period and the total numerical score were 
calculated by Dr. Lava Sharief. The total score was calculated by adding up the 
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pad/tampons counts obtained from each day of the period.  The scores assigned for tampons 
were “1” for each lightly stained tampon, “5” if moderately stained and “10” if it was 
completely saturated with blood. The towels were given ascending scores of “1”, “5” and 
“20”.  Small and large clots scored “1” and “5”, respectively PBAC score ≥ 100 were 
considered a heavy menstrual bleeding (Higham et al., 1990).  
 A bleeding questionnaire was also completed and the bleeding score was calculated based 
on specific symptoms; these included epistaxis, cutaneous symptoms, bleeding from minor 
wounds, muscle hematomas, haemarthrosis, oral cavity bleeding, gastrointestinal bleeding, 
bleeding after tooth extraction, bleeding after surgery, postpartum haemorrhage, and 
menorrhagia. The severity of each symptom was subsequently summarised, using a 
bleeding questionare system ranging from “-1” representing absence of bleeding despite 
haemostatic challenge, “0” representing complete absence of bleeding symptoms, “1” given 
when patient reported presence of bleeding, “2” if the bleeding symptoms required 
evaluation by a physician but no active intervention was needed, “3” if bleeding required 
some kind of intervention by physician, and “4” if blood transfusion or surgery was 
required to control the bleeding (Tosetto et al., 2007). Doctor Lava Sharief was trained to 
complete the questionnaire and score the sheet by a haematologist in the department 
(Appendix 5).  
5.2.2 Laboratory method: 
 Blood samples were taken four to six times during one month period as follows: menstrual 
phase (day 1-5), proliferative phase (day 6-11), periovulatory phase (day 12-17), secretory 
phase (days 18-23), and premenstrual phase (day 24-29).  
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After obtaining written informed consent, blood samples were obtained between 11:00 a.m. 
and 2:00 p.m. after a resting period of 10 minutes. Venous blood samples were collected by 
clean venepuncture, with minimal stasis, into citrate (0.105mol/L) VacutainersTM (BD 
Diagnostics, Oxford, UK), with a ratio of one part anticoagulant to 9 parts whole blood. 
Within one hour of collection platelet poor plasma (PPP) was prepared by double 
centrifugation at ambient temperature (2000g for 10 minutes) and aliquots of PPP were 
frozen to -80ºC. On the day of assay samples were thawed to 37ºC. 
The laboratory method to measure plasma FXIII level was the chromogenic ammonia 
release assay as described in chapter 4. 
5.2.3 Statistical method: 
This study is a pilot study. Practical and statistical constraints suggested that 30 women was 
a feasible recruitment number. Current practice suggests that the normal range for Factor 
XIII activity in women is 70 to 140 IU/dL. Thus, we assumed a mean level of 105 IU/dL 
with a standard deviation of 20 IU/dL between women. A single previous study of eight 
women (Bolis et al., 1982) has investigated the within-woman variation in FXIII levels 
during the menstrual cycle, and found a change of around 30% from late follicular phase 
compared to levels during menstruation (i.e. levels at late follicular phase were 67.2% of 
those seen during menstruation).  
Taking this information, we assumed that the mean change in FXIII will be a reduction 
from 105 to 71 IU/dL. However, we assumed a more conservative drop of 15 IU/dL per 
woman between the two time points, and a conservative within-woman SD of 24 IU/dL. 
Assuming the primary analysis is performed by comparing changes in FXIII between these 
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two time points using a paired t-test and a Type I error of 5%, this sample size of 30 women 
gives a power of 80%. 
The statistical package for social sciences, version 20 (SPSS, Chicago, USA) was used. 
Continuous data were presented as mean ± standard deviation (SD). Paired sample t-test 
was used to compare FXIII activity in different phases of the menstrual cycle to the 
menstrual phase. Comparison of FXIII changes in relation to PBAC score and body mass 
index (BMI) was performed using an unpaired t-test (p ≤ 0.05 was considered statistically 
significant). Because statistical test was performed between four groups, Bonferroni 
correction was performed in order to and p value was considered significant if <0.0125 
5.3 Results 
The demographics of 32 women included in this study are illustrated in Table 5.1. All 
women included in the study were found to be non smokers. Only eight women had a 
previous history of pregnancy with a total of 20 pregnancies; four of them resulted in 
miscarriage. The median PBAC score was 92, ranging from 12 to 920. Bleeding scores 
were “-1” in seven (22%) women, “0” in 22 (68%) women, “1” in one (4%), and “3” in two 
(6%) women. In total, 153 blood samples were collected from the women.  
 
Table 5.2 shows the mean FXIII level during various phases of the menstrual cycle while 
Figure 5.1 and Figure 5.2 show the distribution and the mean trend of FXIII activity during 
each phase of the menstrual cycle. The mean FXIII level was lowest during the menstrual 
and periovulatory phases of the cycle (114 IU/dL) and highest level in the secretory (121 
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IU/dL) and premenstrual (122 IU/dL) phases and this difference was found to be 
statistically significant (p=0.036).  
Table  5.1 Demographics of 32 women with normal menstrual cycle included for this 
study 
Variables Outcome 
Country of origin, No. (%)  
Afro-Caribbean  6 (19) 
UK 9 (28) 
Asian 7 (22) 
Germany 5(16) 
Poland 1(3) 
Iranian 1 (3) 
Spanish 
Turkey 
1 (3) 
2 (6) 
Women with previous miscarriage No. (%)  
Yes 4 (12,5) 
No 28 (87.5) 
Previous pregnancies No. (%)  
None 24 (76) 
1 2 (6) 
2 2 (6) 
3 2 (6) 
4 2 (6) 
BMI (Kg/m2); Mean ±SD (range) 25± 4.5 (19 to 
36.5) 
Age (years); Mean ±SD (range) 28.8± 8 (18 to 42) 
Height (cm); Mean ±SD 162 ±7 
Weight (kg); Mean ±SD 66 ±14 
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Table  5.2 FXIII level (IU/dL) at different phases of menstrual cycle in 32 healthy 
women 
 Week 0 
(Menstrual) 
Week 1 
(proliferative) 
Week 2 
(periovulatory) 
Week 3 
(Secretory) 
Week 4 
(premenstrual) 
Number 
samples 
32 32 32 31 22 
Mean 114 119 114 121 122 
SD 23 26 21 22 27 
Lower range 68 69 72 78 68 
Upper range 248 254 255 273 256 
p-value* - 0.058 0.997 0.036 0.036 
* paired t-test. 
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Figure  5.1 Distribution of FXIII activity (mean ± SD) during each phase of the 
menstrual cycle 
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Figure  5.2  Mean and standard error of the mean for FXIII activity and its trend 
throughout menstrual cycle 
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There was no significant correlation between FXIII activity during the menstrual phase and 
age (p= 0.53) or PBAC score (p=0.53), using Spearman’s correlation coefficient. Among 
the 14 women with PBAC score ≥ 100, the median FXIII activity during the menstrual 
phase of the cycle was 116 IU/dL, this was not statistically different from women with a 
normal PBAC score (113 IU/dL) with p 0.72 (unpaired t-test). There was no correlation 
between FXIII and bleeding scores. 
The women were divided into those with BMI less than 25 kg/m2 (n=13) and greater than 
25 kg/m2 (n=11). No significant difference was observed in FXIII activity at different 
phases of menstrual cycle between the two groups (Table 5.3). 
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Table  5.3  FXIII activity (Mean and SD) at different phases of the menstrual cycle 
between normal and overweight women 
Menstrual Cycle phase FXIII at BMI <25 
kg/m2 (N=13) 
FXIII at BMI >25 kg/m2 
(N=11) 
p 
value* 
Day 1-5 (Menstrual) 111 (25.1) 119 (27.0) 0.46 
Day 6-11 (Proliferative) 116(31.6) 125 (26.5) 0.48 
Day 12-17 (Periovulatory) 112(25.6) 121 (20.9) 0.37 
Day 18-23 (Secretory) 120 (22.9) 122 (21.6) 0.87 
Day 24-29 (Premenstrual) 130 (35.0) 120 (32.4) 0.59 
Variables presented as mean (SD), * Tested using unpaired t-test 
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5.4 Discussion 
In this study, FXIII activity was lowest during the menstrual and periovulatory phases. The 
level of FXIII was significantly higher toward the last two weeks of the cycle compared to 
the menstrual phase. FXIII activity during the menstrual cycle has been studied in one 
longitudinal study by Bolis et al. In that study, blood samples were taken from ten healthy 
women on four occasions during the menstrual cycle. The authors showed a highly 
significant decrease in mean FXIII level during the peri-ovulatory phase (67 IU/dL) 
compared to secretory ( 85 IU/dL) and premenstrual phases (89 IU/dL) with p<0.001 (Bolis 
et al., 1982). However, the FXIII level was not measured during the first five days of the 
cycle (menstrual phase). 
Our study has demonstrated that the FXIII levels can be influenced by natural hormonal 
changes during the menstrual cycle. The lower plasma FXIII activity during menstrual and 
periovulatory phase compared to other phases of the cycle might be attributed to the 
increase in the consumption of this factor for its role in healing, angiogenesis and fibrin 
stabilisation needed during these phases of the cycle. FXIIIa induces a severe reduction in 
the thrombospondin-1 (TSP-1) mRNA and reduce TSP-1 levels in the conditioned medium. 
TSP-1 acts as an angiogenesis inhibitor by preventing endothelial cell proliferation and 
migration, as well as inducing apoptosis (Lawler, 2002). Further mediators for FXIII pro-
angiogenic effects involve upregulation of certain transcription factors, and tyrosine 
phosphorylation and activation of vascular endothelial growth factor receptor-2 (Dardik et 
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al., 2005; Muszbek et al., 2011b). This proangiogenic function of FXIII might be important 
in endometrial healing, regeneration and vascular reproliferation following endometrial 
layer shedding during menstrual cycle as well as ovarian surface at site of follicular rupture 
during ovulation.   
This study did not find any correlation between FXIII level during menstrual phase and 
menstrual bleeding. There was no significant difference in FXIII activity in women with 
heavy menstrual bleeding (PBAC score equal or more than 100) compare to those with 
normal menstrual bleeding. However, it is important to note that the PBAC was used in this 
study to measure menstrual blood loss and this is a simple tool that only allows a semi 
objective assessment of menorrhagia (Kadir et al., 1999b). The PBAC was chosen rather 
than a more objective assessment tool, like alkaline hematin, because it is more practical 
and less expensive. 
Understanding these changes in FXIII during menstrual cycle will help clinicians to 
perform blood tests during appropriate phase of the menstrual cycle and to capture the 
baseline level. The sensitivity of testing for FXIII deficiency can also be increased by 
avoiding testing during menstrual and peri-ovulatory phases of the cycle, which are 
associated with a low FXIII level.  This is of paramount importance in the diagnosis and 
management of women with bleeding disorders. For those affected with mild FXIII 
deficiency, knowledge of FXIII changes during menstrual cycle can help the clinician time 
surgical interventions during the phase with the highest coagulation factor level. This may 
help reduce the risk of bleeding and reduce the need/ the amount of haemostatic cover and 
this in turn, reduces the risk of exposure to unnecessary plasma products. 
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6 CHAPTER SIX:  FACTOR XIII LEVEL IN WOMEN WITH 
RECURRENT MISCARRIAGES 
6.1 Introduction 
Recurrent miscarriage, defined as spontaneous loss of three or more consecutive 
pregnancies occurring before week 20 of pregnancy, affects 1% of women of reproductive 
age (Rai and Regan, 2006).  Although many of the cases are related to identifiable maternal 
or fetal abnormalities, the cause of most cases of recurrent miscarriage remains unknown 
(Li et al., 2002). An adequate utero-placental circulation is essential for maintaining 
pregnancy; this is achieved by sustaining a stable maternal coagulation and fibrinolytic 
system (Buchholz and Thaler, 2003).  
Women with severe congenital FXIII deficiency are a risk factor of  recurrent early 
pregnancy loss (Rodeghiero et al., 1987; Inbal and Kenet, 2003; Asahina et al., 2007).  
Systemic review of literature in chapter 3 showed an overall miscarriage rate of 66% 
among women with severe congenital FXIII deficiency. The miscarriage rate was mainly in 
those not receiving FXIII prophylactic treatment, with a rate of 91% (please refer to the 
results in chapter 3). In a study on 351 women with recurrent miscarriage, seven (2%) of 
the women had a bleeding disorder, one of whom had FXIII deficiency (Bick and 
Hoppensteadt, 2005).  The  minimum FXIII level of 31 IU/dL has been suggested to be 
necessary for maintaining pregnancy in a patient with FXIII deficiency (Peyvandi et al., 
2012). However, it is not known whether a borderline FXIII level (levels below 70 IU/dL) 
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is associated with an increased risk of recurrent miscarriage (Inbal and Muszbek, 2003) and 
whether FXIII assessment should be part of the investigation for women with miscarriage. 
The aim of this study is to examine the plasma FXIII level in women with a history of 
recurrent miscarriage compared to a control group of women with no miscarriage and one 
living child to establish any association between FXIII level and recurrent miscarriage. 
6.2 Materials and methods 
6.2.1 Study design 
This case-control study included 68 women (30 women were recruited at The Royal Free 
Hospital NHS Foundation Trust and 38 women were recruited at Kings College Hospital 
NHS Foundation Trust). The study was approved by the hospitals ethical committees and 
informed consent was obtained from participating women.  
The women included were cases with a history of recurrent miscarriage referred for 
evaluation to the recurrent miscarriage clinics by their general practitioner. The European 
Society for Human Reproduction and Embryology (ESHRE), defines recurrent miscarriage 
as three consecutive pregnancy losses occurring before 20 weeks of gestation (Jauniaux et 
al., 2006). All women underwent a detailed evaluation to exclude other possible causes for 
their miscarriages. Clinical assessment included physical examination, vaginal ultrasound 
examination, thrombophilia screen, hormonal levels (FSH, LH, Progesterone, Prolactine), 
lupus anticoagulant testing, tests for anti-phospholipid antibodies (IgG and IgM anti-
cardiolipin antibodies), thyroid hormone function tests, and chromosomal analysis for both 
partners. Women were included in the study when the results of all previous investigations 
were normal and women attending the clinic for follow-up visit. During this stage, blood 
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samples were taken at least two months following the last pregnancy loss for the purpose of 
measuring FXIII level. 
The control group consisted of 62, age matched, healthy women (30 women recruited from 
The Royal Free Hospital NHS Foundation Trust, 32 women were recruited from Kings 
College Hospital NHS Foundation Trust) from hospital staff recruited for this study 
through poster and leaflet invitations. All control women had no history of miscarriages and 
at least one successful pregnancy with a live child. Women were excluded if there was 
history of thrombo-embolic events or bleeding disorders and those on hormonal 
contraceptives at time of blood sampling. Other exclusion criteria included those on aspirin 
and non steroidal anti-inflammatory medications within five days prior to blood sampling. 
6.2.2 Laboratory Methods:   
Blood samples were obtained between 1:30 p.m. and 4:00 p.m. after a resting period of 10 
minutes. Venous blood samples were collected by clean venepuncture, with minimal stasis, 
into citrate (0.105 mol/L) VacutainersTM (BD Diagnostics, Oxford, UK), with a ratio of one 
part anticoagulant to 9 parts whole blood. Within one hour of collection platelet poor 
plasma (PPP) was prepared by double centrifugation at ambient temperature (2000g for 10 
minutes) and aliquots of PPP were frozen to -80ºC. On the day of assay samples were 
thawed to 37ºC. 
The method of measuring plasma FXIII level is the same described in the material and 
method section of chapter 4.  
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6.2.3 Statistical Analysis:   
The sample size for this study was chosen based on a power calculation that suggested 60 
women would be adequate recruitment number. Current practice suggests that the normal 
range for Factor XIII activity in women is 70 to 140 IU/dL. Thus, we assumed a mean level 
of 105 IU/dL with a SD of 20 IU/dL between women. In a previous study of 26 women 
(Schubring et al., 1990) who presented with spontaneous miscarriage, FXIII activity was 
significantly lower by 15 % compared with a control group of normal pregnant women 
during the same gestational period. Taking this information, we assumed that the mean 
change in FXIII will be a difference from 105 to 98 IU/dL. However we assumed a more 
conservative drop of 15 IU/dL per woman between the two groups, and assumed a 
conservative, within-woman, SD of 24 IU/dL. Assuming the primary analysis is performed 
by comparing changes in Factor XIII between these two groups using a non-paired t-test 
and a Type I error of 5%, this sample size of 60 women gives a power of 80%. 
Numerical variables were presented as mean and their standard error (SE). Comparison of 
the mean FXIII levels between cases and controls was performed using unpaired sample t-
test. For categorical variables, a chi-square test was performed, adjusted with Fisher exact 
test when necessary. Statistical analyses utilised SPSS®, version 20 (SPSS, Chicago, 
USA). The level of statistical significance was set at p< 0.05. 
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6.3 Results: 
Among women with recurrent miscarriage, the median number of miscarriages was three 
(range 3-6). The mean age ± SE was 35 ±0.7 years and 33 ±1.0 years in women with 
recurrent miscarriages and control group, respectively with no significant difference 
between both groups (p=0.142). The median gestational age at time of the first, second, and 
third miscarriage was 8.0 (range 2-18), 8.0 (range 4-17), and 7.0 (range 4-19) weeks, 
respectively.  
As seen in Figure 6.1, the mean ±SE FXIII activity among women with recurrent 
miscarriage was 105±4.0, range 40-205. In the control group, mean ±SE was 111±2.9, 
range 48-181 IU/dL. There was no statistical significant difference between these two 
levels (p=0.23).  Eight (12%) women with recurrent miscarriage had FXIII activity < 70 
IU/dL; this was significantly higher compared to control group with only one (2%) woman 
having FXIII activity <70 IU/dL ( p= 0.034, Fisher exact test). Among the cases with 
recurrent miscarriage, 39 (57%) women had primary miscarriages (defined as recurrent 
miscarriage with no prior live birth) with mean ± SE FXIII activity of 106 ±5.5 IU/dL, 
while 29 (43%) women with a history of secondary miscarriage (defined as recurrent 
miscarriage after a prior live birth) showed a FXIII level of 103 ±6.0 IU/dL. This difference 
was also not statistically significant (p=0.75). 
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Figure  6.1 FXIII activity mean and distribution in women with history of recurrent 
miscarriage compare to control group 
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6.4 Discussion  
This study aimed to investigate the presence of any possible link between level of plasma 
FXIII and occurrence of unexplained recurrent miscarriage in otherwise healthy women. 
This study did not show a statistically significant difference in the mean FXIII level in 
women with history of recurrent miscarriage compared to a control group; however, there 
was a significant difference in the distribution of FXIII level with significant higher number 
of women with low FXIII activity < 70 IU/dL in the recurrent miscarriage group compared 
to the control group. 
Previous studies have tried to examine the association between plasma FXIII level and 
recurrent miscarriage (Ogasawara et al., 2001; Pasquier et al., 2012). In a study among 424 
women with history of recurrent miscarriage, FXIII activity was measured at week four of 
pregnancy. The women were followed up prospectively for the occurrence of miscarriage. 
The study showed no significant difference in the miscarriage rate between those with 
normal versus abnormal FXIII level [47/186 (25.3%) versus 2/10 (20.0%)]. Their normal 
range of FXIII was 52–118 IU/dL, determined by measuring 50 healthy individuals 
(Ogasawara et al., 2001). This study did not compare absolute plasma FXIII activity 
between women with and without consecutive miscarriages, and there was no similar 
comparison with a control group. Furthermore, the definition of the normal range applied in 
this study is debatable as it was based on a small number of individuals.  
In a further study of 26 women presented with spontaneous miscarriage (between 6-14 
weeks of gestation), FXIII activity was significantly lower by 15 % compared with a 
control group of normal pregnant women during same gestational period. The FXIII 
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activity in the group of women with miscarriage returned back to normal when examined 
six weeks after the pregnancy loss (Schubring et al., 1990). One limitation of the study is 
the lack of comparison with a control group of non pregnant women. In addition, it is 
difficult to assess whether the lower level of FXIII seen in the miscarriage group is the 
cause or the result of the miscarriage process. 
A more recent study assessed FXIII-A and FXIII B-subunit antigen levels in 264 women 
with two or more miscarriages in comparison to a same number of control group (women 
with no history of miscarriage and had one living child) and found no significant difference 
between both groups.  However, analysis of a subgroup of 152 women with three or more 
miscarriages (early miscarriage before 20 weeks) showed a slightly higher FXIII-A 
(100.8% vs. 96.0%, P = 0.027, OR 1.011) and FXIII-B (97.6% vs. 93.2%, P = 0.023, OR 
1.012) antigen levels in the women with recurrent miscarriage compared to controls.  The 
study showed no association between FXIII-A and B antigen levels and pregnancy loss, 
except for a reduced odd ratio for pregnancy loss below the 75th (108 IU/dL) and 50th (90 
IU/dL) percentiles, respectively, and only for a subgroup of women with three or more 
recurrent miscarriage. No similar association with FXIII antigen level below 10th percentile 
(70 IU/dL) and 25th percentile was seen (Pasquier et al., 2012). The study, however, did not 
assess FXIII activity.  There were 24 women with FXIII-A antigen levels of < 70 IU/dL in 
the cases compared to 22 women in the control group. The authors thus suggested that the 
mild FXIII-A deficiency seen in the patients and controls is not related to pregnancy loss 
(Pasquier et al., 2012). 
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 Successful implantation involves adequate cytotrophoblast growth to the proper depth of 
the endometrium, thus providing adequate anchorage for the conceptus and promotes 
adaption of uteroplacental circulation (Feng et al., 2000). The formation of the placental 
basal plate matrix, known as Nitabuch layer, involves the activation of the intravenous 
maternal procoagulant cascade, leading to fibrin deposition on the walls of decidual veins 
around the areas of trophoblastic invasion (Craven et al., 2002). FXIII plays an important 
role through forming γ-glutamyl-ε-lysine peptide covalent bonds that cross-links fibrin γ- 
and α-chains (Ariëns et al., 2000). Thus, FXIII behaves as an adhesive protein, promoting 
the binding of fibronectin receptors between the stroma and cytotrophoblasts. 
 FXIII also adheres to fibrinogen and type IV collagen located at the surface of decidual 
cells; thus strengthening the attachment of cytotrophoblast in the endometrium. However, 
in the absence of FXIII, fibrin polymers are aggregated only by weak intermolecular 
hydrogen bonds (Asahina et al., 1998).  Immuno-histochemical staining of implantation 
tissues in women with congenital FXIII deficiency showed poorly formed cytotrophoblastic 
shells and Nitabuch’s layers together with undetectable FXIII at placental bed compared 
with implantation tissues of healthy women (Asahina et al., 2000). 
Possible mechanisms for first trimester pregnancy loss in women with FXIII deficiency 
include a coagulation defect leading to micro-vascular bleeding resulting in fetal loss 
(Hsieh and Nugent, 2008). However, it is not clear whether impaired coagulation alone is 
the primary cause of miscarriage considering the multifunctional nature of FXIII. Another 
possible hypothesis is the influence of FXIII on the innate immune system. FXIII affects 
the complement immune system through incorporating C3 in the fibrin clot and prolonging 
fibrinolysis (Wang et al., 2010; Bagoly et al., 2012). It also augments monocyte and 
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macrophage phagocytic activity and enhances platelet binding to monocyte, which in turn 
localise immune response to the area of injury (Ichinose, 2012). Whether other links exist 
between FXIII and the immune system as a cause of recurrent miscarriage is not fully 
known and would require further studies in the future.  
Although the mean difference in FXIII activity was not statistically significant among 
women with recurrent miscarriage compared to the control group, there were a significantly 
higher number of women with recurrent miscarriage who had FXIII activity < 70 IU/dL 
compared to the control group. It is not clear whether the low level of FXIII activity in this 
subgroup of women is linked to their risk of recurrent miscarriage. FXIII may cross-link 
substrates other than fibrin that are also important for maintaining pregnancy. Some 
heterozygous mutations alter the structure of FXIII with no direct effect on FXIII level and 
FXIII activity. Whether altered FXIII structure contributes to the risk of miscarriage is also 
a possibility. In addition, the presence of other factors (haemostatic, immunological, others) 
may have a synergistic effect on the role of FXIII in inducing pregnancy loss. A study on 
artery thrombotic tissues and pulmonary emboli concluded that PAI-1 polymorphism, in 
combination with FXIII Val34Leu polymorphism have synergestic effect and can increase 
the risk of fibrinolysis impairment through inhibiting the fibrinolytic system activity and 
increasing fibrin network resistance against fibrinolysis (Kohler, 2001). However, this 
synergistic effect was not found in a more recent study comparing 63 women with recurrent 
miscarriage to a control group and found only PAI-1- 4G polymorphism to be a risk factor 
for pregnancy loss but no similar role of FXIII Val34Leu polymorphism (Abalovich et al., 
2002).   
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In conclusion, this study is the first study to assess FXIII activity in women with history of 
recurrent miscarriage and control group of women with no miscarriage and one living child. 
It showed that significantly higher number of women with recurrent miscarriage have FXIII 
level < 70 IU/dL.  It is possible that borderline FXIII activity has a role in pregnancy loss in 
this subgroup of women. Advocating for FXIII level screening among women with 
recurrent miscarriage would require further studies in order to assess their overall systemic 
and local haemostatic parameters.   
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7 CHAPTER SEVEN: OVERALL CONCLUSIONS AND 
SUGGESTIONS FOR FUTURE RESEARCH 
7.1 Overall conclusions 
In conclusion, the systematic review of 192 pregnancies in 121 women with congenital 
FXIII deficiency revealed heavy menstrual bleeding to be a common gynaecological 
problem with a prevalence of 26%. However, this is most likely to be an underestimate as 
most case reports did not provide information on menstrual bleeding. Ovulation bleeding 
was also common and observed in 8% of affected women. Pregnancies in women with 
FXIII deficiency have a significant risk of miscarriage, placental abruption, and PPH if not 
treated. The prevalence of miscarriage in women not on prophylaxis reached as high as 
91%. Therefore, replacement therapy is essential to achieve successful pregnancy and to 
reduce the risk of bleeding during pregnancy, preterm delivery and PPH. 
Our longitudinal study of 32 women of reproductive age during the normal menstrual cycle 
found the mean FXIII level to be lowest during the menstrual and periovulatory phases of 
the cycle (114 IU/dL) and highest in the secretory (121 IU/dL) and premenstrual (122 
IU/dL) phases and this difference was found to be statistically significant (p=0.036). There 
was no significant correlation during the menstrual phase, between FXIII activity and 
menstrual blood loss assessment score (p=0.53). 
The cross sectional study on 376 women during pregnancy and immediate postpartum 
period demonstrated a significant difference in the mean FXIII activity of 112 IU/dL during 
the first trimester compare to second (96 IU/dL) and third (83 IU/dL) trimester as well as 
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postnatal period (90 IU/dL).  The reference range for FXIII activity during the first 
trimester was 55 - 169 IU/dL, for the second trimester was 45 -147 IU/dL, for the third 
trimester 42 - 125 IU/dL and for postnatal period was 61 -137 IU/dL. Knowledge of the 
FXIII reference range is helpful for appropriate management of FXIII deficiency in 
pregnancy. It can also improve our understanding of the role of FXIII in pregnancy 
complications.  
Our case-control study included 68 women with recurrent miscarriage compared with a 
control group of 62 women without history of miscarriage and with at least one successful 
pregnancy. The mean FXIII activity among women with recurrent miscarriage was 105 
IU/dL, while the control group had a mean FXIII activity of 111 IU/dL. There was no 
statistical significant difference between these two levels (p=0.23).  Eight (11.8%) women 
with recurrent miscarriage had FXIII activity < 70 IU/dL; this was significantly higher 
compared to control group with only one (1.6%) woman having FXIII activity <70 IU/dL. 
This thesis highlighted the significant obstetrics and gynaecological morbidity in women 
with congenital FXIII deficiency. The thesis also showed that FXIII level changes 
significantly under hormonal influence during menstrual cycle and during pregnancy. The 
reference range for FXIII level is established during pregnancy and immediate postpartum 
period. The role of FXIII in women with recurrent miscarriage is also explored and 
highlighted the need for further studies. 
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7.2 Suggestions for future research 
7.2.1 Scope for future guideline 
Due to the rarity nature of FXIII deficiency, multicenter studies and/or a web based 
international registry are necessary to properly examine the pregnancy and delivery 
management and outcome in these women. This will also create more evidence to base the 
guidelines for management upon, to ensure best outcome for the mother and her expected 
neoborn. 
Increased awareness among clinicians and a multidisciplinary approach is essential when 
managing the gynaecological and obstetrical issues affecting women with FXIII deficiency. 
7.2.2 Management of pregnancy and labour in FXIII deficient women.  
Our study on normal pregnant women revealed FXIII level to be lower toward the 2nd and 
3rd trimester of pregnancy compared to the 1st trimester and control groups. The exact 
mechanism of such drop in FXIII activity during these stages of pregnancy is not clearly 
understood and need further study. Whether increased transplacental FXIII transport to the 
growing foetus and/or the increased FXIII consumption as part of placental growth are 
attributing to this decline in FXIII level require further studies. Similarly, it is also 
important to investigate whether plasma FXIII activity predict the presence of placental 
insufficiency or its related conditions such as intrauterine growth retardation and 
preeclampsia.  
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The decline in FXIII activity during immediate postpartum period was reported in this 
study when measured during day 0 to 3 post delivery. Future studies are required to define 
the time needed for FXIII level to return back to its pre-pregnancy level. This information 
can be useful in the clinical care of women with FXIII deficiency. Studies in pregnant 
women with FXIII deficiency are required to confirm whether the same pattern of change 
in their FXIII levels occur during pregnancy and postpartum as in the normal population. 
7.2.3 FXIII level during menstrual cycle 
FXIII activity was significantly low during menstrual and periovulatory phases compare to 
the last two weeks of the cycle. However, due to the weak association and the small number 
of women included in this study, it is still not certain whether such variation in FXIII level 
and the timing of blood sample taking during menstrual cycle can significantly affect the 
sensitivity of tests in diagnosis of FXIII deficiency.  
Further future studies may be needed on women with FXIII deficiency to examine whether 
similar trend is also seen during menstrual and periovulatory phases of their cycle. Low 
FXIII levels during these periods, if similarly present in FXIII deficient women, can be 
related to the occurrence of menorrhagia and ovarian bleeding. If so, there might be a need 
to adjust the dose of FXIII prophylaxis during menstruation and ovulation periods. 
7.2.4 Plasma FXIII activity and recurrent pregnancy loss 
Although our study didn’t show a significant difference in mean FXIII activity in women 
with recurrent miscarriages when compared with the control group, there was a 
significantly higher number of women with FXIII <70 IU/dL among those with recurrent 
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miscarriage. Whether this has a significant role in the pregnancy loss in such women need 
further studies. Large studies assessing FXIII levels in correlation with other haemostatic 
factors are required to assess whether a defect in haemostatic process presents a risk for 
early pregnancy loss or pregnancy related bleeding. The role of local endometrial 
haemostatic factors in the process of implantation and early placental development also 
require further research. 
Finally, studies to assess the role of FXIII level systemically or locally within the 
endometrium/decidua in women undergoing in-vitro fertilisation and particularly those with 
recurrent implantation failure are also required.  
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Appendix 1 
Summary of the case reports of women with congenital FXIII deficiency 
 
Authors and year Fisher et al, 1966 Rodeghiero et al, 1987(Rodeghiero et al., 1987) Burrows et al, 
2000(Burrows 
et al., 2000) 
Country                                       Morocco Italy Australia 
Age/age at Dx 
(year) 
29/29 25/18 22/3 
Family History No NS  brother FXIII  
<1U/dl. ICH at 
age 2.  
Consanguineous Yes NS NS 
Abnormal tests Abnormal  clot 
solubility test 
Abnormal clot solubility test. FXIII activity 0.5%. 
Sub unit B 45-60 U/dl 
FXIII  <1U/dl  
Reason for Dx bleeding diathesis & 
repeated miscarriage 
NS Repeated ICH 
at age of 3. 
Treatment Admitted 4 times for 
the pelvic hematoma 
Blood transfusion  
Blood transfusion therapy post tooth extraction 
and retroperitoneal Hg.. External drainage and 
several Units of blood transfused to treat ICH, 
followed by 500U FFP every 3 weeks 
Phenobarbital 
and 
carbamazepine 
for seizure 
Regular 
prophylaxis 
No Substitutive therapy of 300ml-450ml FFP every 
14 days for infertility. Became  pregnant after 2 
months  
One year later at age 21 regular 3 weekly FFP 
resumed in dose of 500U after ICH . 
 While under prophylaxis became  pregnant  
250ml /mo 
pooled plasma. 
& prophylaxis 
250-500IU 
FXIII 
concentrate 
Infertility NS Yes with 2 years history of primary infertility  NS 
Successful 
pregnancy 
 
1 2 1  
Miscarriage 
 
12  Recurrent early miscarriages.Several onsets of 
unexplained delays in the onset of  menstrual 
cycles. Pregnancy test was positive in 5-10 days 
followed by a heavy period 
0 
Prophylaxis 
during pregnancy 
The patient was not on 
any prophylaxis for the 
last 12 pregnancies.  
For the last pregnancy, 
300 ml plasma was 
given every 10days. 
1st pregnancy: 300-450ml of FFP every 14 days. 
Mean pre-infusion FXII level was 2.5U/d.l   
Mean immediate post-infusion level 10 U/dl.  
2nd pregnancy:  500U FXIII concentrate every 
3weeks.  
FXIII 
concentrate 
increased to 
500IU every 
4weeks. 
Maintaining the 
level to 3 U/dl 
Complications 
during pregnancy 
Uneventful NS Uneventful  
 
Prophylaxis for 
delivery 
600ml plasma +1000ml 
fresh blood +300ml 
plasma 8 days postop  
NS 1000IU  
FXIII was 19 
U/dl 
Mode of delivery 
& gestational age 
Elective CS at 9th mo 1st pregnancy Emergency CS for cephalo-pelvic 
disproportion. 2nd pregnancy:  : NS 
Induced NVD 
at 38wk,  
Maternal 
outcome  
Uneventful  
 
Both pregnancies uneventful Uneventful 
Neonatal   outcome  live baby 3000 gm,  Both pregnancies Full term healthy male baby Healthy Boy 
wt. 3065 gm 
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Authors and 
year 
Ikkala et al, 
1964(Ikkala et al., 
1964) 
Girolami et al 
1986(Girolami et al., 
1986)  
Cerenzia et al, 
1999(Cerenzia et al., 
1999)  
Takahashi et al 2007 
Country                                       Finland Italy Germany Japan 
Age/age at Dx 30/30 34/34 32/27 19/4 
Family History No No No NS 
Consanguineou
s 
Yes No No Ns 
Abnormal tests Abnormal  clot 
solubility test 
Abnormal TEG test 
and urea solubility 
test. FXIII<10U/dl 
NS FXIII activity after blood 
transfusion 7%. 
FXIII-A Ag <10%) 
Reason for Dx 1962 severe  intra-
abdominal bleeding 
(ovarian origin)  
Bleeding history 
since age of 8 
following 
tonsillectomy and 
tooth extraction.PPH 
Two attacks of ICH at 
age 15 and 17 
At age of 4, subcutaneous 
haemorrhage on face with 
history of ICH at age 1 
year  
Treatment Blood transfusion 
with removal of 
uterus and adenexia 
NS NS 200 ml Blood transfusion 
Regular 
prophylaxis 
Only after diagnosis 
prior to tooth 
extraction 
NO FXIII concentrate started 
1990 
Yes, FXIII concentrate 
Infertility NS NS NS NS 
Successful 
pregnancy 
 
None 2 One (ended with IUD at 
37 week of gestation with 
placental detachment) 
One (2005) 
Miscarriage 
 
1959-1961  
Repeated habitual  
0 one at 6th wk gestation 
(1991) 
No 
Prophylaxis 
during 
pregnancy 
none NO FXIII concentrate (dose 
not specified) 
500 U FXIII 
(Fibrogammin P) 
concentrate every 2-3 wks, 
maintaining FXIII level 
between 10-20% 
Complications 
during 
pregnancy 
NS None IUD at 37 week gestation At 32 weeks of gestation, 
FXIII level dropped <3%. 
Fibrogammin increased to 
1250 U /week and FXIII 
level raised to 10-20% 
Prophylaxis for 
delivery 
NA None 3000 IU FXIII 
concentrate 
1250 U Fibrogammin 
Mode of 
delivery & 
gestational age 
NA NS NVD at 37 week of 
gestation 
NVD at 39 week 
Maternal 
outcome  
NA PPH following both 
pregnancies 
Uneventful  Uneventful  
Neonatal   
outcome  
NA Two alive babies IUD and delivery of dead 
baby 2600 gm 
A live baby 2842 gm, 
FXIII activity was 21%. 
No bleeding. 
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Authors and year Boda et al, 1989 
 
Kobayashi et al, 1990 Asahina et al, 1998 Asahina et al, 
2000  
Country                                       Hungary Japan 
Age / age at Dx 
(years) 
34/34 23/6 
Family History Her father’s sister died of ICH. 
No other family had bleeding. 
Her brother is heterozygous   
NS 
Consanguineous NS NS 
Abnormal tests Plasma solubility in 5M urea 
<90%. 
FXIII – A subunit was not 
detected and B subunit was 25 
U/dl.  FXIII activity < 5%.  
FXIII 7 U/dl 
Reason for 
diagnosis 
Preparation of operation to 
remove a breast tumour 
Subdural haemorrhage at age of 6 years  
Treatment OCP for treating menorrhagia  Transfused fresh  blood to treat umbilical and Subdural 
bleeding 
Regular prophylaxis FFP given prior to surgery in 
Dec 1986 for breast mass 
removal 
NS 
Infertility Yes because she had history of 
primary infertility and had 8 
subsequent miscarriages 
NS 
Successful 
pregnancy 
1 2 
Miscarriages 8 3 
Prophylaxis during 
pregnancy 
The first spontaneous 
miscarriages occur at 18th week 
of gestation. 
Other 7 miscarriages occurred 
between 8-12 wks . No major 
bleeding disorders 
9th pregnancy: 400 ml FFP 
every 10 days after becoming 
spontaneously pregnant in 
March 1987 
1st pregnancy: Spontaneous miscarriage  at 2 month 
2nd pregnancy: In 1986, vaginal bleeding on 6w5d gestation,. 
Pre-infusion level of FXIII was 24 U/dl.. treated with 500IU 
/wk of FXIII concentrate  
3rd pregnancy: Spontaneous miscarriage at 2 month. 
4th pregnancy: At 5w6d had vaginal bleeding. mean pre-
infusion level of plasma XIII was 18.5 U/dl. Two vials FXIII 
concentrate given and bleeding stopped 
5th pregnancy: pre-infusion level plasma XIII was 23U/dl at 
8w6d. Two vials of prophylactic FXIII concentrate were 
administered at 5w6d. and7w0d. Missed receiving 2 substitute 
therapy at 7w6d and 8w6d. 
Complications 
during pregnancy 
NS 2nd   pregnancy: 2 vial /wk of FXIII concentrate. From 9-
22wk, plasma FXIII ranged from 12-30 U/dl.  In 23rd wk, it 
reduced to 7%. From 24 to 37 wk, FXIII ranged from 10 -30 
U/dl  
4th pregnancy: 1vial per wk started from the onset of bleeding, 
plasma FXIII ranged from 10-20 U/dl. 
At 23wk plasma FXIII dropped to 5 U/dl so the weekly dose 
increased to 2 vial per wk . and the plasma FXIII level was 
from 13-39 U/dl.  No genital bleeding occurred. 
5th pregnancy: Fetal heartbeat disappeared at 9w5d).  
Prophylaxis for 
delivery 
400 ml FFP. Mean post 
infusion level of FXIII was 11 
U/dl 
2nd pregnancy: 4 vials of FXIII Concentrates.  
Patient FXIII level before delivery was 36 U/dl . 
4th pregnancy: 4 vials of FXIII Concentrates patient’s plasma 
XIII before delivery was 52 U/dl. 
Mode of delivery & 
gestational age 
CS at 38 week 2nd  and 4th pregnancy: Normal vaginal delivery on 37 wk   
Maternal outcome  Uneventful 2nd and 4th pregnancy Uneventful with no bleeding 
Neonatal   outcome & 
its treatment 
3100 gm Healthy boy. No sign 
of bleeding, FXIII activity was 
45 U/dl 
2nd  pregnancy: Female infant weighed 2646 g and was in good 
condition. The plasma X III-Ag was 32 U/dl. 
4th pregnancy: Female infant weighed 3,142 g and was in good 
condition. The infant’s plasma X III –Ag was 31 U/dl. 
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Authors and 
year 
Melo et al, 2008 Hanke et al , 2010 Rott et al, 2004 
Country                                       Colombia Germany Germany 
Age/ age at Dx 19/19 32 35/ 35 
Family History two brothers died at 8 and 12 years 
of age .cousin FXIII deficiency at 12 
yrs 
Yes, her sister suffered 
from same disease  
NS 
Consanguineous Yes NS NS 
Abnormal tests PT: 16, PTT 28 
factor XIII activity was of 7.5 IU/dL 
FXIII activity of 40% 
&  Hereditary 
hypofibrinogenaemia  
Prolonged PT& TT, 
Normal aPTT & 
platelet  
FXIII rest activity 50%.  
Genotype showed 
FXIII-B mutation  
Reason for 
diagnosis 
macroscopic Haematurea 
 and profuse post sex bleeding 
NS but the patient was 
reported for spinal 
anaesthesia during  CS 
Five unsuccessful IVF 
Treatment  RBC transfusion post exodontias. 
tranexamic acid (1 gram /6 hours), 3 
U FXIII concentrates of (1/20 kg), 
controlling bleeding. Haematoma 
treated with 7 U cryoprecipitate and 
tranexamic acid. Ovulation bleeding 
treated with 8 U cryoprecipitate 
preoperatively and 2 U packed RBC 
during operation  
NS The 6th IVF treated 
with 2500 IE FXIII-
concentrate i.v. and she 
became pregnant. 
Regular 
prophylaxis 
Yes, cryoprecipitate monthly NS FXIII concentrate 
before the 6th IVF  
Infertility No NS 5 unsuccessful IVF 
Successful preg 1 1 1 
Miscarriages No NO NS 
Prophylaxis 
during 
pregnancy 
cryoprecipitate 6 units monthly NS FXIII- concentrate 
substituted 2500 U 
every 10 days. FXIII 
activity was always 
above 70% during 
pregnancy. No signs of 
hypercoagulability 
occured, d-dimers and 
Prothrombin fragment 
normal. 
Complications 
during 
pregnancy 
Between weeks 29-34 had 
haematurea.  
NO Premature rupture of 
membrane on 38th 
week so she had CS 
Prophylaxis for 
delivery 
Week 39, 8 units of cryoprecipitate 
given prior to CS. 
2gm fibrinogen & 
FXIII 1250IU .  
Preinfusion FXIII 48%. 
Post infusion FXIII 
62%. 
 
Mode of 
delivery & 
gestational age 
39week by CS Elective CS for breech 
presentation at 38 week 
CS on 38th week of 
gestation 
Mat  outcome  uneventful uneventful NS 
Neonatal   
outcome  
Normal test of FXIII  Alive baby healthy, small for date. 
2400 g wt. 
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Authors and 
year 
Gomez Garcia et al, 2001 Saito et al, 1990 
Country                                       Netherland   Japan 
Age /  
age at diagnosis 
1st case: NS/7 
2nd case: NS/31 
32/ 
32 
Family History 1st case: No 
2nd case: Yes, her brother died age 12 from ICH  
Yes, sister had two pregnancies 
with PPH at both times. Plasma 
FXIII activity <10U/dl 
Brother had undetectable FXIII-B. 
Plasma FXIII activity 10U/dl 
Consanguineous NS Yes, parents are cousins 
Abnormal tests 1st  case:  FXIII activity was 0.01 U/ml based on 
ammonia release assay 
2nd  case: FXIII activity was 0.02 U/ml based on 
ammonia release assay 
Low FXIII level of activity 
(24U/dl) 
Undetectable subunit B (<2 U/dl) 
Reduced FXIII-A subunit (14 
U/dl) 
Platelet FXIII A normal (135 
U/dl) 
Reason for 
diagnosis 
1st case: long-lasting superficial bleeding after 
trauma.  
2nd case: lifelong haemorrhagic diathesis, and after 
her brother’s death due to ICH. 
Bleeding at suture sites of 2nd CS. 
Treatment 1st sister: Transfusion therapy for Posttraumatic 
intramuscular bleeding 
2nd sister: FFP for intramuscular hematoma.  
Suture bleeding treated with 5 
units of concentrated Red cells 
and 5 units FFP 
Regular 
prophylaxis 
Since 1971, the sources of factor XIII were plasma, 
cryoprecipitate and, since 1992, plasma-derived 
factor XIII concentrate   
2nd sister= NS 
NS 
Infertility NS No 
Successful preg 1st case:  3  
2nd case: 1 
2 
 
Miscarriage 
 
1st Case: No 
2nd Case: 10 spontaneous miscarriages 
No 
 
Prophylaxis in 
pregnancy 
1st Case: FXIII substitutes 
2nd case : NS 
None 
Complications 
during 
pregnancy 
1st case:  2nd  pregnancy: At 8th month developed 
APH. Other pregnancies had no bleeding  
2nd case: all pregnancies had metrorrhagia at 4th 
month of pregnancy, except one at 7th month 
1st pregnancy: uneventful 
2nd pregnancy: vaginal bleeding 
near term 
Prophylaxis for 
delivery 
1st case: FXIII substitutes for all three pregnancies 
2nd case: NS 
None 
Mode of 
delivery & 
gestational age 
1st case: 2nd pregnancy at 8 month, mode not 
specified 
2nd case: all terminated at 4 month except one at 7mo 
1st pregnancy: CS for 
cephalopelvic disproportion 
2nd pregnancy: CS 
Maternal 
outcome & its 
treatment 
NS 1st: uneventful 
2nd: PPH bleeding treated with 
laprotomy, 5 U of concentrated 
RBCs and 5U FFP 
Neonatal   
outcome  
1st case: healthy 3 boys. All hetrozygose. FXIII 
activity 0.43 U/ml and 0.58 U/ml. Both sons had 
FXIII-A antigen reduce to 50%  
2nd case: all terminated at 4 months except one 
pregnancy delivered a premature died in few days. 
1st pregnancy: Live healthy girl. 
FXIII activity 107% 
2nd pregnancy: full term healthy 
boy, FXIII activity 30%.  
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Authors and year Mikkola et al, 1997 Meili 2002 Singh et al 
2008 
Hamer and Rae 1971 
Country                                       Finland Germany India New Zealand 
Age/ age at Dx 1st sister: 38/19 
2nd sister: 35/16 
27/22 13/1 17/17 
Family History Yes, sister had bleeding symptoms  no NS Yes, one sister had 
umbilical cord bleeding 
and died age 2 due to 
ICH 
2nd sister umbilical 
bleeding  
Mother bleed post 
labour 
Consanguineous NS NS NS No 
Abnormal tests 1st sister: Abnormal clot solubility  
no A-subunit antigen was detectable. 
FXIII activity 0.3%. 
2nd sister: Abnormal clot solubility.  
FXIII activity 0.1%. 
Abnormal gene mutation 
Abnormal clot 
solubility,  
FXIII activity <5% 
based on ammonia 
release assay 
Normal PT, 
APTT 
Abnormal clot 
solubility test 
Reason for 
diagnosis 
1st sister: younger sisters’ bleeding 
symptoms. 
2nd sister: In 1978, was investigated 
for  haematuria, and intramuscular 
hematoma 
corpus luteum 
rupture  
Umbilical 
bleeding 
History of bleeding 
diathesis 
Treatment  Transfusion therapy for intramuscular 
bleeding 
2nd sister: FFP for intramuscular 
hematoma.   
Surgery to 
eliminate gluteal 
haematoma  
laprotomy for 
corpus luteum cyst 
rupture  
surgery and 2 
units of blood 
and 4 units of 
FFP. 
Blood transfusion for 
surgeries. empiric 
treatment  with FFP for 
trauma and dental 
treatment for 3 years  
Regular 
prophylaxis 
1st sister= No 
2nd sister= NS 
factor XIII 
concentrate 
(Fibrogammin)  
500 U//month 
FFP 15 mL 
kg/mo but only 
took it every 
3 - 4 months. 
FFP/4–6 week 
post op 
 
Infertility NS NS NS NS 
Successful preg 1st sister= 2; 
 2nd sister = 0 
1 NS NS 
Miscarriage No NS NS NS 
Prophylaxis 
during pregnancy 
1st sister:  
1st and 2nd pregnancy  
No blood products given 
500 U 
Fibrogammin / 3 
wks from 16th wks  
Increased to 750 U 
/2 wks from 22nd 
week  
NS NS 
Complications 
during 
pregnancy 
1st sister: 
1st pregnancy: At 31 week had APH 
2nd pregnancy: At 37 week had APH 
NS NS NS 
Prophylaxis for 
delivery 
1st sister: 
1st and 2nd pregnancies: FFP 
1000 U 
Fibrogammin   
Keep FXIII 
activity 33U/dl 
NS NS 
Mode of delivery 
& gestational age 
1st sister: 
1st pregnancy at 31 wk CS 
2nd pregnancies at 37 wk CS 
NVD at 37 week a 
healthy boy 
NS NS 
Maternal outcome  NS Normal NS NS 
Neonatal   outcome  Two  healthy baby girl healthy boy NS NS 
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Authors and 
year 
Padmanabhan et al, 2004 Chakravarty et al, 2012 
Country                                       India India 
Age /  
age at 
diagnosis 
Case 1: 29/29 
Case 2: 22/7 
13/1 
Family History Case 1: NS 
Case 2:  Yes, sister  
NS 
Consanguineo
us 
Case 1: Yes,  first cousins 
Case 2: Yes 
NS 
Abnormal tests Case 1: Abnormal Urea solubility test  
Case 2: NS   
NS 
Reason for 
diagnosis 
Case 1: Repeated seven first trimester miscarriages and 
bleeding diathesis  
Case 2: bleeding after tongue injury  
umbilical cord bleed in the 
first week after birth, 
multiple bruises and 
hematoma.  
Treatment  Case 1: Blood transfusion for tooth extraction 
Case 2: Blood transfusion for umbilical bleed 
FFP. Ovarian haematoma 
(2L Blood) removed 
through laproscopy after 2 
U FFP and 1 U blood 
prophylaxis. Intraop FFP, 
packed RB, and 
transexamic acid injection. 
Post op OCP. 
Regular 
prophylaxis 
Case 1: Cryoprecipitate, 1 unit every month for one year until 
got pregnant with the 8th pregnancy. repeated for 6 mo before 
9th preg. 
Case 2: the 1st, 2nd, and 3rd pregnancies were not on 
prophylaxis. In the 4th pregnancy, cryoprecipitate infusion 
advised but not taken  
FFP (15 ml/kg) per month  
But taken irregularly  
Infertility Case 1: NS 
Case 2: 2 maternal uncles with no children  
NA 
Successful 
pregn 
 
Case 1: 1 
Case 2: 0 
NA  
miscarriage 
 
Case 1: 8 
Case 2: 4 
NS 
Prophylaxis 
during 
pregnancy 
Case 1: 8th pregnancy one units cryoprecipitate every 14 days.  
9th  pregnancy from 6 week gestation two units cryoprecipitate / 
14 days. 
Case 2:  None  
NA 
Complications 
during 
pregnancy 
Case 1: 8th pregnancy: Missed miscarriage at 11wk . 
9th pregnancy uneventful. 
Case 2:  
1st:and 2nd  pregnancy: spontaneous miscarriage in first 
trimester. 
 3rd pregnancy: Vaginal bleeding at 5wk.  
4th pregnancy: vaginal bleed at 8 wk 
NA 
Prophylaxis for 
delivery 
Case 1: 9th  pregnancy: 2 units cryoprecipitate  
 
NA 
Mode of 
delivery  
Case 1: 9th pregnancy: Induced NVD at 38wk NA 
Maternal 
outcome  
Case 1: good NA 
Neonatal   
outcome  
Case 1: 9th pregnancy alive baby Normal test of FXIII  NA 
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Authors and year Dargaud et al, 2008  Girolami et al, 1977 
Country                                       France Italy 
Age / age at 
diagnosis 
34/34 Case 1: 30/ 28 
Case 2: 33/33 
Family History NS Yes ( both cases were sisters) 
Consanguineous No No 
Abnormal tests Normal: aPTT, Quick time, platelet, 
fibrinogen, VWF activity, plasma FXIII 
activity  <15IU/dl. very low  FXIII 
activity (2IU/dl). Ag measurement of 
FXIII-A and B subunits normal at 120 and 
130IU/dl,  
Cases 1 and 2 
Normal coagulation pattern.  
Electroimmuno assay showed lack of 
Subunit A, Normal subunit S. 
Reason for 
diagnosis 
 Three spontaneous miscarriages. Case 1. Evaluation of bleeding diathesis 
including APH, PPH. Case 2 screening due 
to sister’s bleeding symptoms. 
Treatment NS No 
Regular 
prophylaxis 
NS No 
Infertility NS  No 
Successful 
pregnancy  
 
1 Case 1: 2  
Case 2: 2 
miscarriage 
 
3  Case 1: 2 miscarriage 
Case 2: No 
Prophylaxis 
during pregnancy 
Only for 4th pregnancy: 
FXIII concentrate 20U/kg every 21 days 
from the beginning of pregnancy 
Case 1. No 
Case 2: No 
Complications 
during pregnancy 
1st pregnancy :miscarriage in 2002 at 
8wk, associated with severe bleeding that 
required transfusion therapy  
2nd pregnancy: miscarriage in 2002 at 
16wk.  
3rd pregnancy: VB after 4thwk,  
miscarriage in 2003 at 12 wks. 
4th pregnancy:  at 12 wk, cervical 
insufficiency treated by Cervical cerclage. 
 At 25 wk, Chorioamnionitis & PRM 
Case 1:  First pregnancy age 19 had APH 
and PPH  
Second pregnancy age 20, had APH, PPH 
Third pregnancy age 23, had miscarriage 
and profuse bleeding. 
Forth pregnancy age 25, had miscarriage 
and profuse bleeding.  
Case 2:  both pregnancies had PPH 
Prophylaxis for 
delivery 
4th pregnancy: A booster dose FXIII 
concentrate 1250U 
Case1: no 
Case 2: No 
Mode of delivery  4th:Premature vaginal delivery at 25 wk Case 1: NS 
Maternal 
outcome & its 
treatment 
3rd pregnancy: Post evacuation sever VB 
and DIC, treated with 10 units of FFP and 
4 units red blood cells, and uterine artery 
embolisation controlled acute bleeding.   
4th: Uneventful 
Case 1:  First pregnancy age 19 had APH 
and PPH treated with 3 unit blood 
transfusion with good response.  
Second pregnancy age 20, had APH, PPH 
and treated with blood transfusion 
Third pregnancy age 23, had miscarriage 
and profuse bleeding. 
Forth pregnancy age 25, had miscarriage 
and profuse bleeding. 
Case 2: Had one unit fresh blood for PPH. 
Neonatal   outcome  4th preg: premature, low birth wt 770 gm.  
Died 7 days after delivery due to ICH 
NS 
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Authors and 
year 
Koseki et al, 
2001 
Lovejoy et al, 2006 Capellato et al, 1987 
Country                                       Japan United States Italy  
Age / age at 
diagnosis 
22/NS NS 34/NS 
Family History NS NS NS 
Consanguineous NS NS NS 
Abnormal tests FXIII <10 
IU/dL 
 FXIII A <12 
IU/dL using 
immunoassay   
Undetectable A2B2 
and FXIII-B subunit 
using urea clot 
solubility test 
FXIII-A <10 IU/dL 
FXIII-B  <10  IU/dL 
Reason for 
diagnosis 
 Postoperative 
bleeding. 
Long history of 
menorrhagia and 
postsurgical bleeding. 
Subcutaneous and postoperative bleeding and 
menorrhagia  
Treatment NS NS NS 
Regular 
prophylaxis 
NS NS NS 
Infertility NS  NS NS 
Successful 
pregnancy  
 
NS NS 2 
miscarriage 
 
NS NS No 
Prophylaxis 
during 
pregnancy 
NS NS NS 
Complications 
during 
pregnancy 
NS NS Both pregnancies had PPH 
Prophylaxis for 
delivery 
NS NS NS 
Mode of 
delivery  
NS NS NS 
Maternal 
outcome & its 
treatment 
NS NS NS 
Neonatal   
outcome  
NS NS NS 
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Appendix 2 
Characteristics of women in case series with congenital FXIII deficiency 
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No.women  22 20 3 6 9 †† 8 5 2 4 3 17 7 ¶ 
Age  NS NS 46,4
5,30 
17-52 20-45 22-
64 
43,24 
22,51
, 33 
NS NS 24, 29, 
14 
18-35  22-
35 
Age at 
Diagnosis 
NS NS NS 13,2,34,
34,7, 20 
NS NS 5,0.5,
16,7,
22 
NS NS 24, 
29,7 
NS NS 
FamilyHx NS NS NS 4/6 3/13 NS 1/5 NS Yes 2/3 11/17 NS 
Consang-
uineous   
3/16 NS 3/3 1/6 NS 0/8 NS NS NS 2/3 NS NS 
Ovulation 
bleeding  
NS 4  NS  NS NS NS NS NS NS NS NS NO 
ICH NS NS 1/3 6/6  0/13 0/8 3/5 NS NS 1/3 2/17 NO 
Menorrha
gia 
I= 4/4 
(3/3) * 
II=7/11 
(3/5) 
III= 0/2 
7/20 
(35%) 
3/3 1/6 1/13 1/8 NS 1/2 2/4 NS NS 3/7 
FXIII 
activity  
NS <5 18,6, 
<3 
< 1.5 20-60 43-
71 
NS < 3  <1 NS NS <2-
10 
Prophylaxi
s 
NS One 
case  
8 U 
cryopp
t 
Only 
two 
case
s 
6/6 
FXIII 
conc 
2500 
FXIII 
conc 
prior 
to CS 
NS NS FFP  NS One 
case 
FFP 
FXIII 
conc 
NS 
RM ** Type 
I&III 
=0/6 
TypeII= 
10/16 
(6/10) * 
3/6 
one 
case 
13 RM 
then 2 
preg 
after 
proph 
One 
had 
13 
One 
had 
5  
NS NS NS NS NS One 
case 
5 
RM 
1st= 8 
(RM) 
2nd= 2 
Miscar
riage 
3rd= 0 
12/17 
one 
misc 
2/17 
two 
misc 
2/17 
three 
misc 
One 
had 2 
misc
arria
ge 
No. 
Women 
had viable 
Pregnancy 
I &III= 
6/6(4/4)
† 
II= 7/16 
(2/10) * 
6/20  NS NS 1/9 2/8 NS NS 0/4 
 
NS 17/17 
at 38 
week  
5/7 
PPH 6/6(4/4† NS NS NS NO 2/8 NS NS  NS NS NO 5/7 
 
**RM=Recurrent Miscarriage   NS= Not specified   PPH = Post partum haemorrhage       
 * When excluding data from Ikkala et al, Fisher et al, Boda et al, Hamer and Rae et al, Kobayashi et al   
 † When excluding Saito et al and Girolami et al 
 †† Only 9/13 women were included with FXIII <70 IU/dL 
¶ All the cases in Ichinosa paper  were separately described in the case reports (Saito et al, Girolami et al 1977 
and 1984, Lovejoy et al, Capellato et al, Koseki et al and Ivaskevicius 2010). 
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Appendix 3 
History of bleeding diathesis among the studied case reports 
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Ikkala et al, 1964 + - - - - - - + - - + - - + 
Fisher et al, 1966 + + + + + + - - - - - - - + 
Hamer and Rae 1971 - - - + - - - - - + + + - - 
Girolami et al, 1977 
-  
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- 
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-  
- 
-  
- 
-  
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- 
+ 
+ 
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Girolami et al, 1986 - - - + - - - + - + - + - - 
Capellato et al, 1987 -  
 
-  
 
-  
 
-  
 
-  
 
-  
 
-  
 
+ -  
 
+  
 
-  
 
+  
 
-  
 
-  
 
Rodeghiero et al, 1987 + - - + - + + + - - - - - - 
Boda et al, 1989 + + - - - - - + + - - - - - 
Saito et al, 1990 - - - - - - - - - + - + - - 
Mikkola et al, 1997 - - 
+ 
+ 
- 
+ 
- 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
Gerenzia et al, 1999 - - - - - - + - - - - - - - 
Kobayashi et al, 1990 
Asahina 1998, 2000 
+ - - - - - + - - + - - - - 
Burrows et al, 2000 - - - - - - + - - - - - - - 
Gomez Garcia et al, 2001 - + 
- 
+ 
- 
+ 
- 
+ 
- 
- 
- 
- 
- 
+ 
- 
+ 
- 
+ 
+ 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
Meili 2002 + + - + + + - - + - - + - + 
Koseki et al, 2003 - - - - - - - - - - - + - - 
Rott et al, 2004 - - - - - - - - - - - - - - 
Padmanabhan et al, 2004 - + 
- 
- 
- 
- 
+ 
- 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Lovejoy et al, 2006 - - - - - - - + - - - + - - 
Takahashi et al 2007 + - - - - - + - + - - - - - 
Dargaud et al, 2008 - - - + - - - - - + - - - - 
Melo et al, 2008 - + + + - - - - - - - - - - 
Singh et al 2008 + + + - - - + - + - - - + + 
Hanke et al , 2010 - - - - - - - - + + - - - - 
Chakravarty et al, 2012 + + - - - - + - - + - - + + 
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Appendix 4 
 
Pictorial Blood Assessment Chart and Scoring System for Assessment of 
Menstrual Blood Loss 
 
 
How to use the PBAC scoring system: 
- During the course of your period record your use of tampons and sanitary towels by 
placing a tally mark under the day next to the box that represents how stained your 
sanitary materials are each time you change them. 
- Record clots by indicating whether they are the size of a 1p or 50p coin in the clots/ 
flooding row under the relevant day. E.g. under day 1 you may say 50p x 1 and 1p x 3. 
- Record any incidences of flooding by placing a tally mark in the clots/ flooding row 
under the relevant day. 
Scores: 
- A lightly stained towel (pic 1) will score 1 point, a moderately stained towel (pic 2) 5 
points, a towel which is saturated with blood (pic 3) will score 20 points. 
- A lightly stained tampon (pic 4) will score 1 point, a moderately stained tampon (pic 5) 
5 points and a tampon that is fully saturated will score 10 points 
- A clot the size of 1p scores 1 point, a 50p sized clot scores 5 points and flooding also 
scores 5 points 
Results 
Once you have finished your period total up your scores. A score of 100 or greater may 
indicate that you have heavy periods and you should seek advice from your doctor. 
However if your score is less than 100 and you have concerns about your period you 
should always consult your GP. 
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NAME:       SCORE: 
DAY START:  
DAY 
TOWEL 1 2 3 4 5 6 7 8 
 
 
 
1 point each 
        
5 points each 
 
        
20 points each         
CLOTS/ 
FLOODING 
Size 5 p = 1 point 
Size 50 p = 5 points 
        
TAMPON 1 2 3 4 5 6 7 8 
1 point each         
5 points each         
10 points each         
CLOTS/ FLOODING 
Size 5 p = 1 point 
Size 50 p = 5 points 
        
Higham et al, (1990), Assessment of menstrual blood loss using a pictorial chart, British Journal of Obstetrics 
& Gynaecology, 97, pp734-739.  
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Appendix 5  Assigned score for each bleeding symptom  
Symptom 
Score 
−1 0 1 2 3 4 
Epistaxis – 
No or 
trivial (less 
than 5) 
>5 or more than 
10′ Consultation only 
Packing or 
cauterization or 
antifibrinolytic 
Blood transfusion 
or replacement 
therapy or 
desmopressin 
Cutaneous – 
No or 
trivial 
(<1 cm) 
>1 cm and no 
trauma Consultation only     
Bleeding from 
minor wounds – 
No or 
trivial (less 
than 5) 
>5 or more than 5′ Consultation only Surgical haemostasis 
Blood transfusion 
or replacement 
therapy or 
desmopressin 
Oral cavity – No Referred at least one Consultation only 
Surgical 
haemostasis or 
antifibrinolytic 
Blood transfusion 
or replacement 
therapy or 
desmopressin 
Gastrointestinal 
bleeding – No 
Associated with 
ulcer, portal 
hypertension, 
haemorrhoids, 
angiodysplasia 
Spontaneous 
Surgical 
hemostasis, blood 
transfusion, 
replacement 
therapy, 
desmopressin, 
antifibrinolytic 
  
Tooth extraction 
No 
bleeding in 
at least two 
extraction 
None done 
or no 
bleeding in 
one 
extraction 
Referred in <25% 
of all procedures 
Referred in >25% 
of all procedures, 
no intervention 
Resuturing or 
packing 
Blood transfusion 
or replacement 
therapy or 
desmopressin 
Surgery 
No 
bleeding in 
at least two 
surgeries 
None done 
or no 
bleeding in 
one surgery 
Referred in <25% 
of all surgeries 
Referred in >25% 
of all procedures, 
no intervention 
Surgical hemostasis 
or antifibrinolytic 
Blood transfusion 
or replacement 
therapy or 
desmopressin 
Menorrhagia – No Consultation only Antifibrinolytics, pill use 
Dilatation and 
currettage, iron 
therapy 
Blood transfusion 
or replacement 
therapy or 
desmopressin or 
hysterectomy 
Postpartum 
hemorrhage 
No 
bleeding in 
at least two 
deliveries 
No 
deliveries 
or no 
bleeding in 
one 
delivery 
Consultation only 
Dilatation and 
currettage, iron 
therapy, 
antifibrinolytics 
Blood transfusion 
or replacement 
therapy or 
desmopressin 
Hysterectomy 
Muscle 
hematomas – Never 
Post trauma no 
therapy 
Spontaneous, no 
therapy 
Spontaneous or 
traumatic, requiring 
desmopressin or 
replacement 
therapy 
Spontaneous or 
traumatic, 
requiring surgical 
intervention or 
blood transfusion 
Haemarthrosis – Never Post trauma no therapy 
Spontaneous, no 
therapy 
Spontaneous or 
traumatic, requiring 
desmopressin or 
replacement 
therapy 
Spontaneous or 
traumatic, 
requiring Surgical 
intervention or 
blood transfusion 
Central nervous 
system bleeding – Never – – 
Subdural, any 
intervention 
Intracerebral, any 
intervention 
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